1
|
Nakamura A, Suzuki S, Kanasugi J, Ejiri M, Hanamura I, Ueda R, Seto M, Takami A. Synergistic Effects of Venetoclax and Daratumumab on Antibody-Dependent Cell-Mediated Natural Killer Cytotoxicity in Multiple Myeloma. Int J Mol Sci 2021; 22:ijms221910761. [PMID: 34639102 PMCID: PMC8509545 DOI: 10.3390/ijms221910761] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/03/2021] [Revised: 09/27/2021] [Accepted: 10/01/2021] [Indexed: 02/06/2023] Open
Abstract
The prognosis of multiple myeloma (MM) has drastically improved owing to the development of new drugs, such as proteasome inhibitors and immunomodulatory drugs. Nevertheless, MM is an extremely challenging disease, and many patients are still refractory to the existing therapies, thus requiring new treatment alternatives. Venetoclax is a selective, orally bioavailable inhibitor of BCL-2 that shows efficacy in MM not only as a single agent but also in combination therapy, especially for MM patients with translocation t(11;14). However, many patients are refractory to this drug. Here, we treated the MM cell lines KMS12PE and KMS27 with a combination treatment of venetoclax targeting BCL-2 and daratumumab targeting CD38 to evaluate the synergistic cytotoxicity of these drugs in vitro. MM cell lines were co-cultured with natural killer (NK) cells at an effector:target ratio of 0.3:1 in the presence of serial concentrations of daratumumab and venetoclax, and the resulting apoptotic MM cells were detected by flow cytometry using annexin V. These results indicated that the antibody-dependent cell-mediated NK cytotoxicity was enhanced in KMS12PE and KMS27 cells harboring t(11;14) with a high BCL-2 expression, suggesting that the combination treatment of venetoclax and daratumumab should be especially effective in patients with these characteristics.
Collapse
Affiliation(s)
- Ayano Nakamura
- Department of Internal Medicine, Division of Hematology, Aichi Medical University School of Medicine, Nagakute 480-1195, Japan; (A.N.); (J.K.); (I.H.); (M.S.); (A.T.)
| | - Susumu Suzuki
- Research Creation Support Center, Aichi Medical University, Nagakute 480-1195, Japan
- Department of Tumor Immunology, Aichi Medical University School of Medicine, Nagakute 480-1195, Japan;
- Correspondence: ; Tel.: +81-561-62-3311 (ext. 11426)
| | - Jo Kanasugi
- Department of Internal Medicine, Division of Hematology, Aichi Medical University School of Medicine, Nagakute 480-1195, Japan; (A.N.); (J.K.); (I.H.); (M.S.); (A.T.)
| | - Masayuki Ejiri
- Department of Pharmacy, University Hospital, Aichi Medical University, Nagakute 480-1195, Japan;
| | - Ichiro Hanamura
- Department of Internal Medicine, Division of Hematology, Aichi Medical University School of Medicine, Nagakute 480-1195, Japan; (A.N.); (J.K.); (I.H.); (M.S.); (A.T.)
| | - Ryuzo Ueda
- Department of Tumor Immunology, Aichi Medical University School of Medicine, Nagakute 480-1195, Japan;
| | - Masao Seto
- Department of Internal Medicine, Division of Hematology, Aichi Medical University School of Medicine, Nagakute 480-1195, Japan; (A.N.); (J.K.); (I.H.); (M.S.); (A.T.)
| | - Akiyoshi Takami
- Department of Internal Medicine, Division of Hematology, Aichi Medical University School of Medicine, Nagakute 480-1195, Japan; (A.N.); (J.K.); (I.H.); (M.S.); (A.T.)
| |
Collapse
|
2
|
Kagami Y, Kato H, Okada Y, Seto M, Yamamoto K. Establishment of an ATLL cell line (YG-PLL) dependent on IL-2 and IL-4, which are replaced by OX40-ligand + HK with poly-L-histidine and dermatan sulfate. J Clin Exp Hematop 2021; 61:145-151. [PMID: 34334531 PMCID: PMC8519244 DOI: 10.3960/jslrt.20058] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022] Open
Abstract
We established an IL-2 and IL-4 (IL2/4) - dependent adult T-cell leukemia/lymphoma (ATLL) cell line (YG-PLL) by adding poly-L-lysine (PLL) to the culture medium. YG-PLL originates from lymphoma cells and contains a defective HTLV-I proviral genome. Although YG-PLL cannot survive without IL-2/4, the follicular dendritic cell (FDC)-like cell line HK expressing OX40-ligand gene (OX40L+HK) inhibited their death in the presence of soluble neutral polymers. After the prevention of cell death, YG-PLL proliferated on OX40L+HK without IL2/4 in the presence of two kinds of positively or negatively charged polymers. In particular, dermatan sulfate and poly-L-histidine supported growth for more than 4 months. Therefore, the original lymphoma cells proliferated transiently in the presence of IL2/4, and their growth arrest was inhibited by the addition of PLL. Furthermore, YG-PLL lost IL2/4 dependency by the following 3-step procedure: preculture with IL2/4 and neutral polymers, 3-day culture with neutral polymer on OX40L+HK to inhibit cell death, and co-culture with OX40L+HK in the presence of the positively and negatively charged polymers. The extracellular environment made by soluble polymers plays a role in the growth of ATLL in vitro.
Collapse
Affiliation(s)
- Yoshitoyo Kagami
- Department of Hematology, Toyota Kosei Hospital, Toyota, Aichi, Japan.,Department of Hematology and Cell Therapy, Aichi Cancer Center Hospital, Nagoya, Aichi, Japan
| | - Harumi Kato
- Department of Hematology and Cell Therapy, Aichi Cancer Center Hospital, Nagoya, Aichi, Japan
| | - Yasutaka Okada
- Department of Clinical Laboratories, Aichi Cancer Center Hospital, Nagoya, Aichi, Japan
| | - Masao Seto
- Division of Hematology, Department of Internal Medicine, Aichi Medical University School of Medicine, Nagakute, Aichi, Japan
| | - Kazuhito Yamamoto
- Department of Hematology and Cell Therapy, Aichi Cancer Center Hospital, Nagoya, Aichi, Japan
| |
Collapse
|
3
|
Saito H, Miyoshi H, Shibayama H, Toda J, Kusakabe S, Ichii M, Fujita J, Fukushima K, Maeda T, Mizuki M, Oritani K, Seto M, Yokota T, Kanakura Y, Hosen N, Ohshima K. High numbers of programmed cell death-1-positive tumor infiltrating lymphocytes correlate with early onset of post-transplant lymphoproliferative disorder. Int J Hematol 2021; 114:53-64. [PMID: 33765256 DOI: 10.1007/s12185-021-03129-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/16/2020] [Revised: 03/05/2021] [Accepted: 03/09/2021] [Indexed: 11/26/2022]
Abstract
Post-transplant lymphoproliferative disorder (PTLD) is a life-threatening complication of transplantation. In addition to reactivation of Epstein-Barr virus in immunocompromised patients, impaired tumor immunity is suggested to be a risk factor for PTLD. However, it remains unclear whether immune suppressive tumor-infiltrating lymphocytes (TILs) correlate with the occurrence or prognosis of PTLD. We analyzed TILs in 26 patients with PTLD to elucidate the clinicopathological significance of the expression of PD-1 and FoxP3, which are associated with exhausted T-cells and regulatory T-cells (Tregs), respectively. Numbers of PD-1+ TILs in the PTLD specimens were significantly higher in patients who developed PTLD early after transplantation (P = 0.0040), while numbers of FoxP3+ TILs were not (P = 0.184). There was no difference in overall response rate regardless of the expression of PD-1 or FoxP3. FoxP3high patients tended to have a shorter time to progression compared with FoxP3low patients, especially in the case of FoxP3high patients with diffuse large B-cell lymphoma-subtype PTLD (P = 0.011), while PD-1high patients did not. These results suggest that T-cell exhaustion may be mainly associated with PTLD development, while immune suppression by Tregs may be dominant in enhanced progression of PTLD following disease occurrence.
Collapse
Affiliation(s)
- Hideaki Saito
- Department of Hematology and Oncology, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, 565-0871, Japan
| | - Hiroaki Miyoshi
- Department of Pathology, Kurume University School of Medicine, Kurume, Japan
| | - Hirohiko Shibayama
- Department of Hematology and Oncology, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, 565-0871, Japan.
| | - Jun Toda
- Department of Hematology and Oncology, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, 565-0871, Japan
| | - Shinsuke Kusakabe
- Department of Hematology and Oncology, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, 565-0871, Japan
| | - Michiko Ichii
- Department of Hematology and Oncology, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, 565-0871, Japan
| | - Jiro Fujita
- Department of Hematology and Oncology, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, 565-0871, Japan
| | - Kentaro Fukushima
- Department of Hematology and Oncology, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, 565-0871, Japan
| | - Tetsuo Maeda
- Department of Hematology and Oncology, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, 565-0871, Japan
- Department of Hematology, Suita Municipal Hospital, Osaka, Japan
| | - Masao Mizuki
- Department of Hematology and Oncology, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, 565-0871, Japan
| | - Kenji Oritani
- Department of Hematology, Graduate School of Medical Sciences, International University of Health and Welfare, Chiba, Japan
| | - Masao Seto
- Department of Pathology, Kurume University School of Medicine, Kurume, Japan
| | - Takafumi Yokota
- Department of Hematology and Oncology, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, 565-0871, Japan
| | - Yuzuru Kanakura
- Department of Hematology and Oncology, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, 565-0871, Japan
- Department of Hematology, Sumitomo Hospital, Osaka, Japan
| | - Naoki Hosen
- Department of Hematology and Oncology, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, 565-0871, Japan
| | - Koichi Ohshima
- Department of Pathology, Kurume University School of Medicine, Kurume, Japan
| |
Collapse
|
4
|
Mitsui T, Sakai S, Li S, Ueno T, Watanuki T, Kobayashi Y, Masuda R, Seto M, Akai H. Magnetic Friedel Oscillation at the Fe(001) Surface: Direct Observation by Atomic-Layer-Resolved Synchrotron Radiation ^{57}Fe Mössbauer Spectroscopy. Phys Rev Lett 2020; 125:236806. [PMID: 33337194 DOI: 10.1103/physrevlett.125.236806] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/09/2020] [Revised: 07/13/2020] [Accepted: 10/16/2020] [Indexed: 06/12/2023]
Abstract
The surface magnetism of Fe(001) was studied in an atomic layer-by-layer fashion by using the in situ iron-57 probe layer method with a synchrotron Mössbauer source. The observed internal hyperfine field H_{int} exhibits a marked decrease at the surface and an oscillatory behavior with increasing depth in the individual upper four layers below the surface. The calculated layer-depth dependencies of the effective hyperfine field |H_{eff}|, isomer shift δ, and quadrupole shift 2ϵ agree well with the observed experimental parameters. These results provide the first experimental evidence for the magnetic Friedel oscillations, which penetrate several layers from the Fe(001) surface.
Collapse
Affiliation(s)
- T Mitsui
- National Institutes for Quantum and Radiological Science and Technology, Sayo, Hyogo 679-5148, Japan
- National Institutes for Quantum and Radiological Science and Technology, Takasaki, Gunma 370-1292, Japan
| | - S Sakai
- National Institutes for Quantum and Radiological Science and Technology, Takasaki, Gunma 370-1292, Japan
| | - S Li
- National Institutes for Quantum and Radiological Science and Technology, Takasaki, Gunma 370-1292, Japan
| | - T Ueno
- National Institutes for Quantum and Radiological Science and Technology, Sayo, Hyogo 679-5148, Japan
- National Institutes for Quantum and Radiological Science and Technology, Takasaki, Gunma 370-1292, Japan
| | - T Watanuki
- National Institutes for Quantum and Radiological Science and Technology, Sayo, Hyogo 679-5148, Japan
- National Institutes for Quantum and Radiological Science and Technology, Takasaki, Gunma 370-1292, Japan
| | - Y Kobayashi
- Institute for Integrated Radiation and Nuclear Science, Kyoto University, Asashironishi, Kumatori, Osaka 590-0494, Japan
| | - R Masuda
- Faculty of Science and Technology, Hirosaki University, Bunkyocho, Hirosaki, Aomori 036-8152, Japan
| | - M Seto
- National Institutes for Quantum and Radiological Science and Technology, Sayo, Hyogo 679-5148, Japan
- Institute for Integrated Radiation and Nuclear Science, Kyoto University, Asashironishi, Kumatori, Osaka 590-0494, Japan
| | - H Akai
- The Institute for Solid State Physics, The University of Tokyo, Kashiwa, Chiba 277-8581, Japan
| |
Collapse
|
5
|
Yoshida N, Miyoshi H, Arakawa F, Nakashima K, Kawamoto K, Seto M, Ohshima K. Cytokine-related genes play critical roles in extrafollicular growth of follicular lymphoma cells. Hematol Oncol 2020; 38:673-679. [PMID: 32835439 DOI: 10.1002/hon.2795] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/17/2020] [Revised: 08/05/2020] [Accepted: 08/21/2020] [Indexed: 01/11/2023]
Abstract
Follicular lymphoma (FL) is a germinal center-derived B-cell lymphoma that is known to proliferate in the intrafollicular region. However, lymphoma cells can be identified in the extrafollicular regions, which are related to disease dissemination. We purified the intrafollicular and extrafollicular regions of FL cells by laser microdissection and conducted microarray analysis in order to characterize the gene expression profiles of FL cells from both regions. BCL2 and genes of germinal B-cell markers clearly separated intrafollicular and extrafollicular regions of reactive follicular hyperplasia, suggesting the adequacy of the current analysis. In FL cases, cytokine-related genes were significantly enriched in extrafollicular regions compared with those in the intrafollicular regions. In intrafollicular regions of FL, cell-cycle-related genes were enriched. We found that the FL cells in the extrafollicular region more strongly expressed IL3RA and CXCL12 than those of intrafollicular regions. The cytokines might be also derived from stroma cells in the extrafollicular regions, which may initiate activation and migration of the tumor cells to this region. Our results suggest that FL cell interaction with surrounding stroma cells plays an important role in the pathophysiology of FL and that such interactions should be a good target for therapy.
Collapse
Affiliation(s)
- Noriaki Yoshida
- Department of Pathology, Kurume University School of Medicine, Kurume, Fukuoka, Japan.,Department of Clinical Studies, Radiation Effects Research Foundation, Hiroshima, Japan
| | - Hiroaki Miyoshi
- Department of Pathology, Kurume University School of Medicine, Kurume, Fukuoka, Japan
| | - Fumiko Arakawa
- Department of Pathology, Kurume University School of Medicine, Kurume, Fukuoka, Japan
| | - Kazutaka Nakashima
- Department of Pathology, Kurume University School of Medicine, Kurume, Fukuoka, Japan
| | - Keisuke Kawamoto
- Department of Pathology, Kurume University School of Medicine, Kurume, Fukuoka, Japan
| | - Masao Seto
- Department of Pathology, Kurume University School of Medicine, Kurume, Fukuoka, Japan
| | - Koichi Ohshima
- Department of Pathology, Kurume University School of Medicine, Kurume, Fukuoka, Japan
| |
Collapse
|
6
|
Murakami S, Suzuki S, Hanamura I, Yoshikawa K, Ueda R, Seto M, Takami A. Combining T-cell-based immunotherapy with venetoclax elicits synergistic cytotoxicity to B-cell lines in vitro. Hematol Oncol 2020; 38:705-714. [PMID: 32822067 DOI: 10.1002/hon.2794] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/29/2020] [Revised: 08/17/2020] [Accepted: 08/18/2020] [Indexed: 01/19/2023]
Abstract
Alterations of B-cell lymphoma 2 (BCL-2) family proteins contribute to the survival of B-cell malignancies. Recently, venetoclax, a BCL-2 inhibitor, was approved for B-cell chronic lymphocytic leukemia therapy and is being investigated in clinical trials for a variety of hematologic cell malignancies. Furthermore, combination therapy with other molecularly targeted drugs was reported to be more effective than monotherapy. However, combining venetoclax with immunotherapy based on T-cells has not been tested. Because both venetoclax and granzyme B activate the mitochondrial apoptosis pathway by targeting different BCL-2 family molecules, it is possible that combinations of venetoclax with immunotherapy will be effective treatments. We examined the effect of combining venetoclax with immunotherapy using an in vitro model system involving cytomegalovirus (CMV) pp65 antigen-specific cytotoxic T-cells (CMV-CTLs) as the effector cells and CMVpp65 antigen-expressing B-cell lines as the target cells. Cytotoxicity of CMV-CTLs to the target B-cell lines was enhanced by venetoclax with combination index values of 0.47-0.83. This suggests that venetoclax synergizes with T-cell-based immunotherapy to affect B-cell malignancies. Interestingly, venetoclax synergized not only with antigen-specific cytotoxicity but also with nonspecific cytotoxicity. Importantly, CMV-CTLs could be expanded in the presence of venetoclax at the maximum concentration (5 μM) that induced apoptosis in resting CMV-CTLs. B-cell lymphoma-extra large (BCL-xL) expression in CMV-CTLs increased transiently after activation by CMVpp65-transfected B-cell lines, indicating that the expression of BCL-xL was important for the effectiveness of combination treatment with venetoclax. These findings suggest that T-cell-based immunotherapy combined with venetoclax is effective against B-cell malignancies.
Collapse
Affiliation(s)
- Satsuki Murakami
- Division of Hematology, Department of Internal Medicine, Aichi Medical University School of Medicine, Nagakute, Aichi, Japan
| | - Susumu Suzuki
- Research Creation Support Center, Aichi Medical University, Nagakute, Aichi, Japan.,Department of Tumor Immunology, Aichi Medical University School of Medicine, Nagakute, Aichi, Japan
| | - Ichiro Hanamura
- Division of Hematology, Department of Internal Medicine, Aichi Medical University School of Medicine, Nagakute, Aichi, Japan
| | - Kazuhiro Yoshikawa
- Research Creation Support Center, Aichi Medical University, Nagakute, Aichi, Japan
| | - Ryuzo Ueda
- Department of Tumor Immunology, Aichi Medical University School of Medicine, Nagakute, Aichi, Japan
| | - Masao Seto
- Division of Hematology, Department of Internal Medicine, Aichi Medical University School of Medicine, Nagakute, Aichi, Japan
| | - Akiyoshi Takami
- Division of Hematology, Department of Internal Medicine, Aichi Medical University School of Medicine, Nagakute, Aichi, Japan
| |
Collapse
|
7
|
Yanagida E, Miyoshi H, Takeuchi M, Yoshida N, Nakashima K, Yamada K, Umeno T, Shimasaki Y, Furuta T, Seto M, Ohshima K. Clinicopathological analysis of immunohistochemical expression of CD47 and SIRPα in adult T-cell leukemia/lymphoma. Hematol Oncol 2020; 38:680-688. [PMID: 32569413 DOI: 10.1002/hon.2768] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/06/2020] [Revised: 06/04/2020] [Accepted: 06/18/2020] [Indexed: 12/12/2022]
Abstract
The interaction of CD47 and signal-regulatory protein alpha (SIRPα) induces "don't eat me signal", leading suppression of phagocytosis. This signal can affect the clinical course of malignant disease. Although CD47 and SIRPα expression are associated with clinicopathological features in several neoplasms, the investigation for adult T-cell leukemia/lymphoma (ATLL) has not been well-documented. This study aimed to declare the association between CD47 and SIRPα expression and clinicopathological features in ATLL. We performed immunostaining on 73 biopsy samples and found that CD47 is primarily expressed in tumor cells, while SIRPα is expressed in non-neoplastic stromal cells. CD47 positive cases showed significantly higher FoxP3 (P = .0232) and lower CCR4 (P = .0214). SIRPα positive cases presented significantly better overall survival than SIRPα negative cases (P = .0132). SIRPα positive cases showed significantly HLA class I (P = .0062), HLA class II (P = .0133), microenvironment PD-L1 (miPD-L1) (P = .0032), and FoxP3 (P = .0229) positivity. In univariate analysis, SIRPα expression was significantly related to prognosis (Hazard ratio [HR] 0.470; 95% confidence interval [CI] 0.253-0.870; P = .0167], although multivariate analysis did not show SIPRα as an independent prognostic factor. The expression of SIRPα on stromal cells reflects activated immune surveillance mechanism in tumor microenvironment and induce good prognosis in ATLL. More detailed studies for gene expression or genomic abnormalities will disclose clinical and biological significance of the CD47 and SIRPα in ATLL.
Collapse
Affiliation(s)
- Eriko Yanagida
- Department of Pathology, Kurume University School of Medicine, Kurume, Japan
| | - Hiroaki Miyoshi
- Department of Pathology, Kurume University School of Medicine, Kurume, Japan
| | - Mai Takeuchi
- Department of Pathology, Kurume University School of Medicine, Kurume, Japan
| | - Noriaki Yoshida
- Department of Pathology, Kurume University School of Medicine, Kurume, Japan.,Department of Clinical Studies, Radiation Effects Research Foundation, Hiroshima, Japan
| | - Kazutaka Nakashima
- Department of Pathology, Kurume University School of Medicine, Kurume, Japan
| | - Kyohei Yamada
- Department of Pathology, Kurume University School of Medicine, Kurume, Japan
| | - Takeshi Umeno
- Department of Pathology, Kurume University School of Medicine, Kurume, Japan
| | - Yasumasa Shimasaki
- Department of Pathology, Kurume University School of Medicine, Kurume, Japan
| | - Takuya Furuta
- Department of Pathology, Kurume University School of Medicine, Kurume, Japan
| | - Masao Seto
- Department of Pathology, Kurume University School of Medicine, Kurume, Japan
| | - Koichi Ohshima
- Department of Pathology, Kurume University School of Medicine, Kurume, Japan
| |
Collapse
|
8
|
Moritsubo M, Miyoshi H, Matsuda K, Yoshida N, Nakashima K, Yanagida E, Yamada K, Takeuchi M, Suzuki T, Muta H, Umeno T, Furuta T, Seto M, Ohshima K. TACC3 expression as a prognostic factor in aggressive types of adult T-cell leukemia/lymphoma patients. Int J Lab Hematol 2020; 42:842-848. [PMID: 32744749 DOI: 10.1111/ijlh.13289] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/06/2020] [Revised: 06/15/2020] [Accepted: 06/18/2020] [Indexed: 11/28/2022]
Abstract
INTRODUCTION Adult T-cell leukemia/lymphoma (ATLL) is a malignant peripheral T-cell neoplasm associated with human T-cell leukemia virus type-1 (HTLV-1). The acute and lymphoma subtypes are regarded as aggressive ATLLs, and the overall survival (OS) of patients remains poor. Transforming acidic coiled-coil-containing protein 3 (TACC3) regulates microtubules, which are associated with cancer-related proteins overexpressed in various cancers. Such a relationship has not been reported in hematopoietic tumors, including ATLL. METHODS We examined tissue microarrays of histological samples from 92 cases of aggressive ATLL and assessed clinical features, including TACC3 protein expression levels. RESULTS Compared with TACC3-low, TACC3-high ATLL patients were significantly older (P < .001), with a tendency toward pleomorphic variant over other morphological classifications (P = .019). TACC3-high patients (median survival time [MST] 10.6 months, confidence interval [CI] [6.27-15.6]) had poorer OS compared to TACC3-low patients (MST 20 months, CI [9.43-38.5]) (P = .0168). Moreover, multivariate analysis on TACC3 expression levels suggests that TACC3-high is an independent significant prognostic factor (HR, 1.700; 95% CI, 1.037-2.753; P = .0355). CONCLUSION Certain drugs that inhibit TACC3-overexpressing neoplastic cells are used clinically. Further studies might highlight a key role for TACC3 in the oncogenesis and progression of ATLL.
Collapse
Affiliation(s)
- Mayuko Moritsubo
- Department of Pathology, Kurume University School of medicine, Kurume, Fukuoka, Japan
| | - Hiroaki Miyoshi
- Department of Pathology, Kurume University School of medicine, Kurume, Fukuoka, Japan
| | - Kotaro Matsuda
- Department of Pathology, Kurume University School of medicine, Kurume, Fukuoka, Japan.,Department of Orthopedic surgery, Kurume University School of medicine, Kurume, Fukuoka, Japan
| | - Noriaki Yoshida
- Department of Pathology, Kurume University School of medicine, Kurume, Fukuoka, Japan.,Department of Clinical Studies, Radiation Effects Research Foundation, Hiroshima, Hiroshima, Japan
| | - Kazutaka Nakashima
- Department of Pathology, Kurume University School of medicine, Kurume, Fukuoka, Japan
| | - Eriko Yanagida
- Department of Pathology, Kurume University School of medicine, Kurume, Fukuoka, Japan
| | - Kyohei Yamada
- Department of Pathology, Kurume University School of medicine, Kurume, Fukuoka, Japan
| | - Mai Takeuchi
- Department of Pathology, Kurume University School of medicine, Kurume, Fukuoka, Japan
| | - Takaharu Suzuki
- Department of Pathology, Kurume University School of medicine, Kurume, Fukuoka, Japan
| | - Hiroko Muta
- Department of Pathology, Kurume University School of medicine, Kurume, Fukuoka, Japan
| | - Takeshi Umeno
- Department of Pathology, Kurume University School of medicine, Kurume, Fukuoka, Japan
| | - Takuya Furuta
- Department of Pathology, Kurume University School of medicine, Kurume, Fukuoka, Japan
| | - Masao Seto
- Department of Pathology, Kurume University School of medicine, Kurume, Fukuoka, Japan
| | - Koichi Ohshima
- Department of Pathology, Kurume University School of medicine, Kurume, Fukuoka, Japan
| |
Collapse
|
9
|
Kanno H, Miyoshi H, Yoshida N, Sudo T, Nakashima K, Takeuchi M, Nomura Y, Seto M, Hisaka T, Tanaka H, Okuda K, Akagi Y, Ohshima K. Differences in the immunosurveillance pattern associated with DNA mismatch repair status between right-sided and left-sided colorectal cancer. Cancer Sci 2020; 111:3032-3044. [PMID: 32449240 PMCID: PMC7419035 DOI: 10.1111/cas.14495] [Citation(s) in RCA: 17] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/22/2020] [Revised: 04/28/2020] [Accepted: 05/13/2020] [Indexed: 12/25/2022] Open
Abstract
Tumor location and immunity play important roles in the progression of colorectal cancer (CRC). This study aimed to investigate the differences in the immunosurveillance pattern between right‐ and left‐sided CRC and analyze their association with clinicopathologic features, including mismatch repair (MMR) status. We included surgically resected stage II/III CRC cases and evaluated the immunohistochemical findings of HLA class I, HLA class II, programmed cell death‐ligand 1 (PD‐L1), PD‐1, CTLA‐4, CD3, CD4, CD8, TIA‐1, T‐bet, GATA3, RORγT, Foxp3, and CD163. A total of 117 patients were included in the analyses; of these, 30 and 87 had right‐ and left‐sided cancer, respectively. Tumor immunity varied according to the tumor location in the overall cohort. Analysis of the tumors excluding those with DNA mismatch repair (MMR) deficiency also revealed that tumor immunity differed according to the tumor location. In right‐sided colon cancer (CC), high expression of Foxp3 (P = .0055) and TIA‐1 (P = .0396) were associated with significantly better disease‐free survival (DFS). High CD8 (P = .0808) and CD3 (P = .0863) expression tended to have better DFS. Furthermore, in left‐sided CRC, only high PD‐L1 expression in the stroma (P = .0426) was associated with better DFS. In multivariate analysis, high Foxp3 expression in right‐sided CC was an independent prognostic factor for DFS (hazard ratio, 7.6445; 95% confidence interval, 1.2091‐150.35; P = .0284). In conclusion, the immunosurveillance pattern differs between right‐ and left‐sided CRC, even after adjusting for MMR deficiency.
Collapse
Affiliation(s)
- Hiroki Kanno
- Department of Surgery, Kurume University School of Medicine, Kurume, Japan
| | - Hiroaki Miyoshi
- Department of Pathology, Kurume University School of Medicine, Kurume, Japan
| | - Naohiro Yoshida
- Department of Surgery, Kurume University School of Medicine, Kurume, Japan
| | - Tomoya Sudo
- Department of Surgery, Kurume University School of Medicine, Kurume, Japan
| | - Kazutaka Nakashima
- Department of Pathology, Kurume University School of Medicine, Kurume, Japan
| | - Mai Takeuchi
- Department of Pathology, Kurume University School of Medicine, Kurume, Japan
| | - Yoriko Nomura
- Department of Surgery, Kurume University School of Medicine, Kurume, Japan
| | - Masao Seto
- Department of Pathology, Kurume University School of Medicine, Kurume, Japan
| | - Toru Hisaka
- Department of Surgery, Kurume University School of Medicine, Kurume, Japan
| | - Hiroyuki Tanaka
- Department of Surgery, Kurume University School of Medicine, Kurume, Japan
| | - Koji Okuda
- Department of Surgery, Kurume University School of Medicine, Kurume, Japan
| | - Yoshito Akagi
- Department of Surgery, Kurume University School of Medicine, Kurume, Japan
| | - Koichi Ohshima
- Department of Pathology, Kurume University School of Medicine, Kurume, Japan
| |
Collapse
|
10
|
Kazama R, Miyoshi H, Takeuchi M, Miyawaki K, Nakashima K, Yoshida N, Kawamoto K, Yanagida E, Yamada K, Umeno T, Suzuki T, Kato K, Takizawa J, Seto M, Akashi K, Ohshima K. Combination of CD47 and signal-regulatory protein-α constituting the "don't eat me signal" is a prognostic factor in diffuse large B-cell lymphoma. Cancer Sci 2020; 111:2608-2619. [PMID: 32342603 PMCID: PMC7385345 DOI: 10.1111/cas.14437] [Citation(s) in RCA: 21] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/15/2019] [Revised: 04/10/2020] [Accepted: 04/16/2020] [Indexed: 12/21/2022] Open
Abstract
The interaction between CD47 and signal‐regulatory protein‐α (SIRPα) inhibits phagocytosis, thus affecting the clinical outcomes of neoplastic diseases. Although CD47 upregulation is associated with poor prognosis in several malignancies, the effect of SIRPα expression and its coexpression with CD47 remains unclear. This study aimed to investigate the clinicopathologic effect of CD47 and SIRPα expression in diffuse large B‐cell lymphoma (DLBCL). Immunostaining of 120 biopsy samples showed that CD47 is primarily expressed in tumor cells, whereas SIRPα is expressed in nonneoplastic stromal cells, mostly macrophages. CD47high cases showed higher MYC protein expression and lower MYC translocation. The SIRPαhigh cases presented significantly shorter overall survival (OS) and progression‐free survival (PFS) than SIRPαlow cases in the activated B‐cell (ABC) subtype of DLBCL (P = .04 and P = .02, respectively). Both CD47high and SIRPαhigh presented significantly shorter OS and PFS than other cases among all DLBCL patients (P = .01 and P = .004, respectively), and the ABC type (P = .04 and P = .008, respectively) but not the germinal center B‐cell type. Both CD47high and SIRPαhigh yielded a constant independent prognostic value for OS and PFS in multivariate analysis (hazard ratio [HR], 2.93; 95% confidence interval [CI], 1.20‐7.43; P = .02; and HR, 2.87; 95% CI, 1.42‐5.85; P = .003, respectively). To the best of our knowledge, this is the first study to report that combinatorial CD47 and SIRPα expression is a potential independent prognostic factor for DLBCL. Evaluation of CD47 and SIRPα expression could be useful before CD47 blockade therapy.
Collapse
Affiliation(s)
- Ryo Kazama
- Department of Pathology, School of Medicine, Kurume University, Kurume, Japan.,Department of Internal Medicine, Sakai City Medical Center, Sakai, Japan
| | - Hiroaki Miyoshi
- Department of Pathology, School of Medicine, Kurume University, Kurume, Japan
| | - Mai Takeuchi
- Department of Pathology, School of Medicine, Kurume University, Kurume, Japan
| | - Kohta Miyawaki
- Department of Pathology, School of Medicine, Kurume University, Kurume, Japan.,Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan
| | - Kazutaka Nakashima
- Department of Pathology, School of Medicine, Kurume University, Kurume, Japan
| | - Noriaki Yoshida
- Department of Pathology, School of Medicine, Kurume University, Kurume, Japan.,Department of Clinical Studies, Radiation Effects Research Foundation, Hiroshima, Japan
| | - Keisuke Kawamoto
- Department of Hematology, Endocrinology and Metabolism, Niigata University Faculty of Medicine, Niigata, Japan
| | - Eriko Yanagida
- Department of Pathology, School of Medicine, Kurume University, Kurume, Japan
| | - Kyohei Yamada
- Department of Pathology, School of Medicine, Kurume University, Kurume, Japan
| | - Takeshi Umeno
- Department of Pathology, School of Medicine, Kurume University, Kurume, Japan
| | - Takaharu Suzuki
- Department of Pathology, School of Medicine, Kurume University, Kurume, Japan.,Department of Hematology, Endocrinology and Metabolism, Niigata University Faculty of Medicine, Niigata, Japan
| | - Koji Kato
- Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan
| | - Jun Takizawa
- Department of Hematology, Endocrinology and Metabolism, Niigata University Faculty of Medicine, Niigata, Japan
| | - Masao Seto
- Department of Pathology, School of Medicine, Kurume University, Kurume, Japan
| | - Koichi Akashi
- Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan
| | - Koichi Ohshima
- Department of Pathology, School of Medicine, Kurume University, Kurume, Japan
| |
Collapse
|
11
|
Takeuchi M, Miyoshi H, Nakashima K, Kawamoto K, Yamada K, Yanagida E, Muta H, Moritsubo M, Umeno T, Suzuki T, Seto M, Ohshima K. Comprehensive immunohistochemical analysis of immune checkpoint molecules in adult T cell leukemia/lymphoma. Ann Hematol 2020; 99:1093-1098. [PMID: 32157421 DOI: 10.1007/s00277-020-03967-x] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/11/2019] [Accepted: 02/15/2020] [Indexed: 10/24/2022]
Abstract
Acute or lymphomatous type adult T cell leukemia/lymphoma (ATLL) is an aggressive hematopoietic malignancy with poor prognosis. We previously reported that programmed cell death ligand 1 (PD-L1) expression could predict ATLL outcomes. However, the roles of other immune checkpoint molecules remain largely unknown in ATLL. Our aim in this study was to explore the clinicopathological impacts of immune checkpoint molecules in ATLL. Immunohistochemistry was performed in 69 ATLL patients with antibodies against the following: PD-L1, programmed cell death ligand 2 (PD-L2), OX40, OX40 ligand (OX40L), CD137, CD137 ligand (CD137L), Galectin-9, T cell immunoglobulin mucin-3 (Tim-3), cytotoxic T lymphocyte associated protein-4 (CTLA-4), lymphocyte activating-3 (LAG-3), CD80, CD86, glucocorticoid-induced tumor necrosis factor receptor-related protein (GITR), GITR ligand (GITRL), and programmed death-1 (PD-1). Immune checkpoint molecules were variably expressed on neoplastic and/or microenvironmental cells. Expression of PD-1, OX40L, Galectin-9, and PD-L1 was nearly mutually exclusive on neoplastic cells, suggesting that immune checkpoint pathways differ in patients. Microenvironmental expression of PD-L1, OX40L, and Tim-3 was significantly associated with better overall survival (log-rank test; P =0.0004, 0.0394, and 0.0279, respectively). Univariate and multivariate analyses with clinical prognostic factors identified microenvironmental expression of PD-L1 and OX40L, and age (> 70 years) as significant prognostic factors. This is the first comprehensive analysis of ATLL immune checkpoint molecules. Our results may provide information on new therapeutic strategies in ATLL.
Collapse
Affiliation(s)
- Mai Takeuchi
- Department of Pathology, Kurume University School of Medicine, Asahimachi 67, Kurume, Fukuoka, 830-0011, Japan
| | - Hiroaki Miyoshi
- Department of Pathology, Kurume University School of Medicine, Asahimachi 67, Kurume, Fukuoka, 830-0011, Japan.
| | - Kazutaka Nakashima
- Department of Pathology, Kurume University School of Medicine, Asahimachi 67, Kurume, Fukuoka, 830-0011, Japan
| | - Keisuke Kawamoto
- Department of Hematology, Endocrinology and Metabolism, Faculty of Medicine, Niigata University, Niigata, 951-8520, Japan
| | - Kyohei Yamada
- Department of Pathology, Kurume University School of Medicine, Asahimachi 67, Kurume, Fukuoka, 830-0011, Japan
| | - Eriko Yanagida
- Department of Pathology, Kurume University School of Medicine, Asahimachi 67, Kurume, Fukuoka, 830-0011, Japan
| | - Hiroko Muta
- Department of Pathology, Kurume University School of Medicine, Asahimachi 67, Kurume, Fukuoka, 830-0011, Japan
| | - Mayuko Moritsubo
- Department of Pathology, Kurume University School of Medicine, Asahimachi 67, Kurume, Fukuoka, 830-0011, Japan
| | - Takeshi Umeno
- Department of Pathology, Kurume University School of Medicine, Asahimachi 67, Kurume, Fukuoka, 830-0011, Japan
| | - Takaharu Suzuki
- Department of Pathology, Kurume University School of Medicine, Asahimachi 67, Kurume, Fukuoka, 830-0011, Japan.,Department of Hematology, Endocrinology and Metabolism, Faculty of Medicine, Niigata University, Niigata, 951-8520, Japan
| | - Masao Seto
- Department of Pathology, Kurume University School of Medicine, Asahimachi 67, Kurume, Fukuoka, 830-0011, Japan
| | - Koichi Ohshima
- Department of Pathology, Kurume University School of Medicine, Asahimachi 67, Kurume, Fukuoka, 830-0011, Japan
| |
Collapse
|
12
|
Suzuki T, Miyoshi H, Shimono J, Kawamoto K, Arakawa F, Furuta T, Yamada K, Yanagida E, Takeuchi M, Seto M, Sone H, Takizawa J, Ohshima K. Clinicopathological analysis of splenic red pulp low-grade B-cell lymphoma. Pathol Int 2020; 70:280-286. [PMID: 32052529 DOI: 10.1111/pin.12909] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/12/2019] [Accepted: 01/16/2020] [Indexed: 12/31/2022]
Abstract
Primary splenic low-grade B-cell lymphoma of the red pulp comprises hairy cell leukemia (HCL) and splenic B-cell lymphoma/leukemia, unclassifiable (SPLL-U). SPLL-U is a rare disease that includes subtypes of a hairy cell leukemia-variant (HCL-v), splenic diffuse red pulp small B-cell lymphoma (SDRPL) and other types that are known as narrow sense SPLL-U (SPLL-U-NS). Notably, limited information is available regarding the BRAF mutation (V600E) and cyclin D3 expression in subtypes of SPLL-U. Therefore, we performed a pathological analysis of the BRAF mutation (V600E) and characterized pathological features of SPLL-U. We reviewed the pathological findings of 12 SPLL-U cases. The 12 cases considered included two cases of HCL-v, six cases of SPLL-U-NS and four undetermined cases. The BRAF mutation (V600E) was detected in three cases, which were all SPLL-U-NS. Cases with the BRAF mutation (V600E) have increased levels of CD103 expression and decreased cyclin D3 and cyclin D1 expression compared with cases that lacked the BRAF mutation. These findings suggest that the BRAF mutation might play a significant role in SPLL-U. Therefore, the significance of the BRAF mutation should be evaluated via genomic or transcriptional analyses of a large cohort of SPLL-U patients.
Collapse
Affiliation(s)
- Takaharu Suzuki
- Department of Pathology, Kurume University, School of Medicine, Fukuoka, Japan.,Department of Hematology, Endocrinology and Metabolism, Faculty of Medicine, Niigata University, Niigata, Japan
| | - Hiroaki Miyoshi
- Department of Pathology, Kurume University, School of Medicine, Fukuoka, Japan
| | - Joji Shimono
- Department of Pathology, Kurume University, School of Medicine, Fukuoka, Japan
| | - Keisuke Kawamoto
- Department of Hematology, Endocrinology and Metabolism, Faculty of Medicine, Niigata University, Niigata, Japan
| | - Fumiko Arakawa
- Department of Pathology, Kurume University, School of Medicine, Fukuoka, Japan
| | - Takuya Furuta
- Department of Pathology, Kurume University, School of Medicine, Fukuoka, Japan
| | - Kyohei Yamada
- Department of Pathology, Kurume University, School of Medicine, Fukuoka, Japan
| | - Eriko Yanagida
- Department of Pathology, Kurume University, School of Medicine, Fukuoka, Japan
| | - Mai Takeuchi
- Department of Pathology, Kurume University, School of Medicine, Fukuoka, Japan
| | - Masao Seto
- Department of Pathology, Kurume University, School of Medicine, Fukuoka, Japan
| | - Hirohito Sone
- Department of Hematology, Endocrinology and Metabolism, Faculty of Medicine, Niigata University, Niigata, Japan
| | - Jun Takizawa
- Department of Hematology, Endocrinology and Metabolism, Faculty of Medicine, Niigata University, Niigata, Japan
| | - Koichi Ohshima
- Department of Pathology, Kurume University, School of Medicine, Fukuoka, Japan
| |
Collapse
|
13
|
Kawamoto K, Miyoshi H, Seto M, Kimura H, Ohshima K. [Clinical features of adult-onset chronic active Epstein-Barr virus infection]. Rinsho Ketsueki 2019; 60:944-952. [PMID: 31484894 DOI: 10.11406/rinketsu.60.944] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
Chronic active Epstein-Barr virus infection (CAEBV) presents with mononucleosis-like symptoms such as chronic persistent or recurrent pyrexia, lymphadenopathy, and hepatosplenomegaly because of the reactivation of Epstein-Barr virus (EBV) as demonstrated by the recurrence of EBV-infected cells. The mechanism of CAEBV remains obscure, and CAEBV can lead to fatal conditions such as hemophagocytic syndrome and malignant lymphoma by clonal expansion of EBV-infected T- or NK-cells. Without hematopoietic stem cell transplantation, CAEBV has a poor prognosis. CAEBV is listed in the revised 2016 World Health Organization classification as a chronic active EBV infection of T- and NK-cell types, systemic form, among EBV-positive T- and NK-cell lymphoproliferative diseases of childhood. However, similar clinical conditions have been reported in adult patients. Therefore, we investigated the clinical features of adult patients with CAEBV-like features (adult-onset CAEBV) in a relatively small number of cases. Additionally, genetic alterations related to CAEBV development have also been reported. Along with these results, we reviewed the clinical characteristics of adult-onset CAEBV.
Collapse
Affiliation(s)
- Keisuke Kawamoto
- Department of Hematology, Endocrinology, and Metabolism, Faculty of Medicine, Niigata University.,Department of Pathology, Kurume University School of Medicine
| | - Hiroaki Miyoshi
- Department of Pathology, Kurume University School of Medicine
| | - Masao Seto
- Department of Pathology, Kurume University School of Medicine
| | - Hiroshi Kimura
- Department of Virology, Faculty of Medicine, Nagoya University
| | - Koichi Ohshima
- Department of Pathology, Kurume University School of Medicine
| |
Collapse
|
14
|
Takeuchi M, Yamada K, Seto M, Ohshima K, Miyoshi H. COMPREHENSIVE IMMUNOHISTOCHEMICAL ANALYSIS OF IMMUNE CHECKPOINT MOLECULES IN ADULT T-CELL LEUKEMIA/LYMPHOMA. Hematol Oncol 2019. [DOI: 10.1002/hon.34_2631] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Affiliation(s)
- M. Takeuchi
- Department of Pathology; Kurume University; Kurume Japan
| | - K. Yamada
- Department of Pathology; Kurume University; Kurume Japan
| | - M. Seto
- Department of Pathology; Kurume University; Kurume Japan
| | - K. Ohshima
- Department of Pathology; Kurume University; Kurume Japan
| | - H. Miyoshi
- Department of Pathology; Kurume University; Kurume Japan
| |
Collapse
|
15
|
Saito H, Shibayama H, Miyoshi H, Toda J, Kusakabe S, Ichii M, Fujita J, Fukushima K, Yokota T, Maeda T, Mizuki M, Oritani K, Seto M, Ohshima K, Kanakura Y. THE INFLUENCE OF TUMOR IMMUNE MICROENVIRONMENT AND TUMOR IMMUNITY ON THE PATHOGENESIS, TREATMENT AND PROGNOSIS OF POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDERS (PTLD). Hematol Oncol 2019. [DOI: 10.1002/hon.15_2630] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Affiliation(s)
- H. Saito
- Department of Hematology and Oncology; Osaka University Graduate School of Medicine; Osaka Japan
| | - H. Shibayama
- Department of Hematology and Oncology; Osaka University Graduate School of Medicine; Osaka Japan
| | - H. Miyoshi
- Department of Pathology; Kurume University School of Medicine; Kurume Japan
| | - J. Toda
- Department of Hematology and Oncology; Osaka University Graduate School of Medicine; Osaka Japan
| | - S. Kusakabe
- Department of Hematology and Oncology; Osaka University Graduate School of Medicine; Osaka Japan
| | - M. Ichii
- Department of Hematology and Oncology; Osaka University Graduate School of Medicine; Osaka Japan
| | - J. Fujita
- Department of Hematology and Oncology; Osaka University Graduate School of Medicine; Osaka Japan
| | - K. Fukushima
- Department of Hematology and Oncology; Osaka University Graduate School of Medicine; Osaka Japan
| | - T. Yokota
- Department of Hematology and Oncology; Osaka University Graduate School of Medicine; Osaka Japan
| | - T. Maeda
- Department of Hematology and Oncology; Osaka University Graduate School of Medicine; Osaka Japan
| | - M. Mizuki
- Department of Hematology and Oncology; Osaka University Graduate School of Medicine; Osaka Japan
| | - K. Oritani
- Department of Hematology; International University of Health and Welfare; Narita Japan
| | - M. Seto
- Department of Pathology; Kurume University School of Medicine; Kurume Japan
| | - K. Ohshima
- Department of Pathology; Kurume University School of Medicine; Kurume Japan
| | - Y. Kanakura
- Department of Hematology and Oncology; Osaka University Graduate School of Medicine; Osaka Japan
| |
Collapse
|
16
|
Yoshida N, Seto M, Ohshima K. [Heterogeneity of genomic alterations and clinical aspects in peripheral T-cell lymphoma: future perspectives]. Rinsho Ketsueki 2019; 60:271-280. [PMID: 31068555 DOI: 10.11406/rinketsu.60.271] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
Peripheral T-cell lymphoma (PTCL) is a heterogeneous group of lymphoid malignancies. Several recent comprehensive genomic studies characterize the genomic alterations of each PTCL type and reveal the complexity and heterogeneity. The updated World Health Organization classification has precisely distinguished "lymphoma" from "lymphoproliferative disorder" and has included a new entity based on the tumor phenotypes. Although establishing the classifications based on genomic alterations has been difficult because of heterogeneity, the genomic alterations may support the diagnosis. Establishing genomic alterations that act as predictive markers for clinical courses and/or therapeutic targets is needed in future studies using genomic alteration information. Since patients with PTCL generally have poor prognosis, establishing the target and standard therapies is one of the major issues to be addressed. In addition to clinicopathological and genomic analyses, patient-derived xenograft models can provide these therapeutic strategies. Integration of analyzed data is considered to promote future PTCL studies, leading to improved PTCL prognosis.
Collapse
Affiliation(s)
- Noriaki Yoshida
- Department of Pathology, Kurume University School of Medicine.,Department of clinical studies, Radiation Effects Research Foundation
| | - Masao Seto
- Department of Pathology, Kurume University School of Medicine
| | - Koichi Ohshima
- Department of Pathology, Kurume University School of Medicine
| |
Collapse
|
17
|
Matsuoka T, Fujihisa H, Hirao N, Ohishi Y, Mitsui T, Masuda R, Seto M, Yoda Y, Shimizu K, Machida A, Aoki K. Erratum: Structural and Valence Changes of Europium Hydride Induced by Application of High-Pressure H_{2} [Phys. Rev. Lett. 107, 025501 (2011)]. Phys Rev Lett 2019; 122:179901. [PMID: 31107077 DOI: 10.1103/physrevlett.122.179901] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/03/2019] [Indexed: 06/09/2023]
Abstract
This corrects the article DOI: 10.1103/PhysRevLett.107.025501.
Collapse
|
18
|
Takeuchi M, Miyoshi H, Asano N, Yoshida N, Yamada K, Yanagida E, Moritsubo M, Nakata M, Umeno T, Suzuki T, Komaki S, Muta H, Furuta T, Seto M, Ohshima K. Human leukocyte antigen class II expression is a good prognostic factor in adult T-cell leukemia/lymphoma. Haematologica 2019; 104:1626-1632. [PMID: 30630986 PMCID: PMC6669171 DOI: 10.3324/haematol.2018.205567] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/28/2018] [Accepted: 01/09/2019] [Indexed: 12/13/2022] Open
Abstract
Attenuated human leukocyte antigen (HLA) class I expression is implicated as a major immune escape mechanism in several types of tumor. We previously reported that HLA class I/β2 microglobulin and programmed death ligand-1 expression are prognostic factors in adult T-cell leukemia/lymphoma. A recent report suggested that HLA class II expression is also an important prognostic factor for the clinical outcome of programmed death-1 blockade therapy in recurrent/refractory Hodgkin lymphoma. This prompted us to evaluate HLA class II expression in adult T-cell leukemia/lymphoma and to compare the findings with the patients’ clinicopathological features. Of the 132 biopsy specimens examined from newly diagnosed patients, lymphoma cells were positive for HLA class II expression in 44 patients (33.3%), whereas programmed death ligand-1 expression was observed on neoplastic cells from nine patients (6.9%) and on stromal cells in the tumor microenvironment in 83 cases (62.9%). HLA class II-positive cases showed a significantly better overall survival compared to the HLA class II-negative cases (P<0.0001). Patients positive for HLA class II and programmed death ligand-1 microenvironmental expression had significantly better prognosis than the other groups (P<0.0001). HLA class II-positive and HLA class II-negative groups also showed a significant difference in complete remission rate (P=0.0421), HLA class I/β2 microglobulin expression (P=0.0165), and the number of programmed death-1-positive tumor infiltrating cells (P=0.0020). HLA class II expression was a prognostic factor for overall survival both in univariate and multivariate analyses (P<0.0001 and P=0.0007, respectively). Our study reveals that HLA class II is a novel prognostic factor in adult T-cell leukemia/lymphoma.
Collapse
Affiliation(s)
- Mai Takeuchi
- Department of Pathology, Kurume University School of Medicine, Kurume, Fukuoka
| | - Hiroaki Miyoshi
- Department of Pathology, Kurume University School of Medicine, Kurume, Fukuoka
| | - Naoko Asano
- Department of Molecular Diagnostics, Nagano Prefectural Shinshu Medical Center, Suzaka, Nagano
| | - Noriaki Yoshida
- Department of Pathology, Kurume University School of Medicine, Kurume, Fukuoka.,Department of Clinical Studies, Radiation Effects Research Foundation, Hiroshima, Japan
| | - Kyohei Yamada
- Department of Pathology, Kurume University School of Medicine, Kurume, Fukuoka
| | - Eriko Yanagida
- Department of Pathology, Kurume University School of Medicine, Kurume, Fukuoka
| | - Mayuko Moritsubo
- Department of Pathology, Kurume University School of Medicine, Kurume, Fukuoka
| | - Michiko Nakata
- Department of Pathology, Kurume University School of Medicine, Kurume, Fukuoka
| | - Takeshi Umeno
- Department of Pathology, Kurume University School of Medicine, Kurume, Fukuoka
| | - Takaharu Suzuki
- Department of Pathology, Kurume University School of Medicine, Kurume, Fukuoka
| | - Satoru Komaki
- Department of Pathology, Kurume University School of Medicine, Kurume, Fukuoka
| | - Hiroko Muta
- Department of Pathology, Kurume University School of Medicine, Kurume, Fukuoka
| | - Takuya Furuta
- Department of Pathology, Kurume University School of Medicine, Kurume, Fukuoka
| | - Masao Seto
- Department of Pathology, Kurume University School of Medicine, Kurume, Fukuoka
| | - Koichi Ohshima
- Department of Pathology, Kurume University School of Medicine, Kurume, Fukuoka
| |
Collapse
|
19
|
Shimono J, Miyoshi H, Yoshida N, Kato T, Sato K, Sugio T, Miyawaki K, Kurita D, Sasaki Y, Kawamoto K, Imaizumi Y, Kato K, Nagafuji K, Akashi K, Seto M, Teshima T, Ohshima K. Analysis of GNA13 Protein in Follicular Lymphoma and its Association With Poor Prognosis. Am J Surg Pathol 2018; 42:1466-1471. [PMID: 30307409 PMCID: PMC6266301 DOI: 10.1097/pas.0000000000000969] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
GNA13 is a G protein involved in modulating tumor proliferative capacity, infiltration, metastasis, and migration. Genomic alteration of GNA13 was frequently observed in follicular lymphoma (FL). In this study, we examined 167 cases of FL by immunostaining of GNA13 using tissue microarray to evaluate the clinical significance. There were 26 GNA13-positive cases (15.6%) and 141 GNA13-negative cases (84.4%). GNA13-positive cases had a higher incidence of early progression of disease for which disease progression was recognized within 2 years compared with GNA13-negative cases (P=0.03). There were no significant differences in other clinicopathologic factors including histological grade, BCL2-IGH translocation, immunohistochemical phenotype, and Follicular Lymphoma International Prognostic Index. In addition, overall survival and progression-free survival were poorer in GNA13-positive cases than in GNA13-negative cases (P=0.009 and 0.005, respectively). In multivariate analysis, GNA13 positivity was found to be a poor prognostic factor for overall survival and progression-free survival. Thus, GNA13 protein expression was an independent prognostic factor and may affect disease progression in FL.
Collapse
Affiliation(s)
- Joji Shimono
- Departments of Pathology
- Department of Hematology, Faculty of Medicine, Hokkaido University, Sapporo
| | | | | | - Takeharu Kato
- Department of Hematology, Sasebo City General Hospital, Sasebo
- Department of Hematology, Atomic Bomb Disease and Hibakusha Medicine Unit, Atomic Bomb Disease Institute, Nagasaki University, Nagasaki
| | | | - Takeshi Sugio
- Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medicine Sciences, Fukuoka, Japan
| | - Kohta Miyawaki
- Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medicine Sciences, Fukuoka, Japan
| | | | | | | | - Yoshitaka Imaizumi
- Department of Hematology, Atomic Bomb Disease and Hibakusha Medicine Unit, Atomic Bomb Disease Institute, Nagasaki University, Nagasaki
| | - Koji Kato
- Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medicine Sciences, Fukuoka, Japan
| | - Koji Nagafuji
- Division of Hematology and Oncology, Hematology, School of Medicine, Kurume University, Kurume
| | - Koichi Akashi
- Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medicine Sciences, Fukuoka, Japan
| | | | - Takanori Teshima
- Department of Hematology, Faculty of Medicine, Hokkaido University, Sapporo
| | | |
Collapse
|
20
|
Yanagida E, Miyoshi H, Kawamoto K, Nakashima K, Matsuda K, Yamada K, Muto R, Nagafuji K, Seto M, Ohshima K. Clinicopathological analysis of immunohistochemical expression of retinoic acid–related orphan receptor-γt in peripheral T-cell lymphoma, not otherwise specified. Hum Pathol 2018; 79:86-92. [DOI: 10.1016/j.humpath.2018.05.002] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/10/2018] [Revised: 04/25/2018] [Accepted: 05/02/2018] [Indexed: 12/23/2022]
|
21
|
Shimono J, Miyoshi H, Kiyasu J, Kamimura T, Eto T, Miyagishima T, Nagafuji K, Seto M, Teshima T, Ohshima K. Clinicopathological analysis of polyploid diffuse large B-cell lymphoma. PLoS One 2018; 13:e0194525. [PMID: 29641580 PMCID: PMC5894967 DOI: 10.1371/journal.pone.0194525] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/07/2017] [Accepted: 03/05/2018] [Indexed: 01/24/2023] Open
Abstract
Polyploid chromosomes are those with more than two sets of homologous chromosomes. Polyploid chromosomal abnormalities are observed in various malignant tumors. The prognosis in such cases is generally poor. However, there are no studies examining the prognosis of diffuse large B-cell lymphoma (DLBCL) with polyploid chromosomal abnormalities. Therefore, we statistically compared the clinicopathological features between polyploid DLBCL and DLBCL without polyploid abnormalities. Herein, 51 polyploid DLBCL and 53 control (without polyploid chromosomal abnormalities) cases were examined. G-banding method was employed to define polyploidy by cytogenetic analysis. Subsequently, flow cytometric immunophenotyping and immunohistochemical staining were performed. Polyploid DLBCL was defined as DLBCL with either near-tetraploid or greater number of chromosomes, as detected by the G-band. In a survival analysis, a significantly worse overall survival (OS) was observed for polyploid DLBCL (p = 0.04; p = 0.02 in cases who received R-CHOP regimens). In a multivariate analysis of OS, polyploid chromosomal abnormalities were an independent prognostic factor. Our results suggest that polyploid chromosomal abnormalities detected through G-band may represent a new poor prognostic factor for DLBCL.
Collapse
Affiliation(s)
- Joji Shimono
- Department of Pathology, Kurume University, School of Medicine, Kurume, Japan.,Department of Hematology, Hokkaido University Faculty of Medicine, Sapporo, Japan
| | - Hiroaki Miyoshi
- Department of Pathology, Kurume University, School of Medicine, Kurume, Japan
| | - Junichi Kiyasu
- Department of Hematology, Iizuka hospital, Iizuka, Japan
| | | | - Tetsuya Eto
- Department of Hematology, Hamanomachi Hospital, Fukuoka, Japan
| | | | - Koji Nagafuji
- Department of Hematology, Kurume University, School of Medicine, Kurume, Japan
| | - Masao Seto
- Department of Pathology, Kurume University, School of Medicine, Kurume, Japan
| | - Takanori Teshima
- Department of Hematology, Hokkaido University Faculty of Medicine, Sapporo, Japan
| | - Koichi Ohshima
- Department of Pathology, Kurume University, School of Medicine, Kurume, Japan
| |
Collapse
|
22
|
Kawamoto K, Miyoshi H, Suzuki T, Kiyasu J, Yokoyama S, Sasaki Y, Sone H, Seto M, Takizawa J, Ohshima K. Expression of programmed death ligand 1 is associated with poor prognosis in myeloid sarcoma patients. Hematol Oncol 2018; 36:591-599. [PMID: 29602174 DOI: 10.1002/hon.2506] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/07/2017] [Revised: 01/26/2018] [Accepted: 02/11/2018] [Indexed: 12/19/2022]
Abstract
Myeloid sarcoma (MS) is a rare condition and is an extramedullary tumour of immature myeloid cells. It is now known that the programmed death 1 (PD-1)/programmed death ligand 1 (PD-L1) pathway suppresses the host antitumor responses and that these products are expressed on both tumour cells and tumour-infiltrating cells in various malignancies. However, little is known about the significance of PD-1/PD-L1 expression on tumour cells and tumour microenvironmental cells in MS. To investigate the clinicopathological significance of PD-1/PD-L1 expression in MS, we analyzed 98 patients by immunohistochemistry. Of these, 10.2% of cases had neoplastic tumour cells positive for PD-L1 (nPD-L1+ ). However, the rate of nPD-L1+ was <5% (range: 0.27 to 2.97%). On the other hand, PD-L1 expression on 1 or more of stromal cells in the tumour microenvironment (miPD-L1+ ) was observed in 37.8% of cases. Because all nPD-L1+ cases expressed PD-1 on less than 5% of tumour cells, we compared the miPD-L1+ and miPD-L1- groups. There was a correlation between miPD-L1+ status and the number of PD-1-expressing tumour -infiltrating lymphocytes (PD-1+ TILs; P = .0229). miPD-L1+ was found to be associated with poorer overall survival and progression-free survival (P = .00392, P = .00261, respectively). Multivariate analysis also confirmed miPD-L1+ to be an independent poor prognostic factor. In conclusion, our study indicated that the immunotherapy blocking the PD-1/PD-L1 pathway may improve the clinical outcome of MS.
Collapse
Affiliation(s)
- Keisuke Kawamoto
- Department of Pathology, Kurume University School of Medicine, Kurume, Japan.,Department of Hematology, Endocrinology and Metabolism, Faculty of Medicine, Niigata University, Niigata, Japan
| | - Hiroaki Miyoshi
- Department of Pathology, Kurume University School of Medicine, Kurume, Japan
| | - Takaharu Suzuki
- Department of Hematology, Endocrinology and Metabolism, Faculty of Medicine, Niigata University, Niigata, Japan
| | - Junichi Kiyasu
- Department of Hematology, Iizuka Hospital, Iizuka, Japan
| | - Shintaro Yokoyama
- Department of Pathology, Kurume University School of Medicine, Kurume, Japan
| | - Yuya Sasaki
- Department of Pathology, Kurume University School of Medicine, Kurume, Japan
| | - Hirohito Sone
- Department of Hematology, Endocrinology and Metabolism, Faculty of Medicine, Niigata University, Niigata, Japan
| | - Masao Seto
- Department of Pathology, Kurume University School of Medicine, Kurume, Japan
| | - Jun Takizawa
- Department of Hematology, Endocrinology and Metabolism, Faculty of Medicine, Niigata University, Niigata, Japan
| | - Koichi Ohshima
- Department of Pathology, Kurume University School of Medicine, Kurume, Japan
| |
Collapse
|
23
|
Asano N, Miyoshi H, Kato T, Shimono J, Yoshida N, Kurita D, Sasaki Y, Kawamoto K, Ohshima K, Seto M. Expression pattern of immunosurveillance-related antigen in adult T cell leukaemia/lymphoma. Histopathology 2018; 72:945-954. [PMID: 29297942 DOI: 10.1111/his.13461] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/25/2017] [Revised: 12/20/2017] [Accepted: 12/28/2017] [Indexed: 12/21/2022]
Abstract
AIMS Adult T cell leukaemia/lymphoma (ATLL) is an aggressive malignancy with a poor prognosis. Human leucocyte antigen (HLA) and β2 microglobulin (β2M) serve as key molecules in tumour immunity, and their expression is reduced frequently in tumour cells. Programmed cell death (PD)-1/PD-ligand1 (PD-L1) interactions play a role in escape of tumour cells from T cell immunity. Therefore, this study aimed to determine the clinicopathological relevance of HLA and β2M expressions in ATLL cells and PD-L1 expression in lymphoma or stromal cells and predict the overall survival of patients with ATLL. METHODS AND RESULTS We analysed a total of 123 biopsy samples from patients newly diagnosed with ATLL by using immunohistochemical analysis. Of the patients enrolled, 91 (74%) were positive for HLA (in cell membrane, 60 patients), 89 (72%) were positive for β2M (in cell membrane, 54 patients) and 48 (39%) were positive for both HLA and β2M in the cell membrane (HLAm+ β2Mm+ ). No significant clinical differences other than prognosis were found between the HLAm+ β2Mm+ group and the other groups. Immunophenotypical evaluation revealed significantly higher rates of CD30-positive lymphoma cells (P = 0.003) and PD-L1-positive stromal cells in microenvironments (miPD-L1high ) (P = 0.011) of the HLAm+ β2Mm+ group than in the other groups. The HLAm+ β2Mm+ group had a significantly better prognosis that the other groups (P = 0.0096), and patients showing HLAm+ β2Mm+ with miPD-L1high had the most favourable prognosis among all groups. CONCLUSIONS The membranous expression of HLA and β2M is likely to reflect the immune response and would be useful to predict prognosis before starting ATLL therapy.
Collapse
Affiliation(s)
- Naoko Asano
- Department of Molecular Diagnostics, Nagano Prefectural Shinshu Medical Center, Suzaka, Japan.,Department of Pathology, Kurume University School of Medicine, Kurume, Japan
| | - Hiroaki Miyoshi
- Department of Pathology, Kurume University School of Medicine, Kurume, Japan
| | - Takeharu Kato
- Department of Pathology, Kurume University School of Medicine, Kurume, Japan
| | - Joji Shimono
- Department of Pathology, Kurume University School of Medicine, Kurume, Japan
| | - Noriaki Yoshida
- Department of Pathology, Kurume University School of Medicine, Kurume, Japan
| | - Daisuke Kurita
- Department of Pathology, Kurume University School of Medicine, Kurume, Japan
| | - Yuya Sasaki
- Department of Pathology, Kurume University School of Medicine, Kurume, Japan
| | - Keisuke Kawamoto
- Department of Pathology, Kurume University School of Medicine, Kurume, Japan
| | - Koichi Ohshima
- Department of Pathology, Kurume University School of Medicine, Kurume, Japan
| | - Masao Seto
- Department of Pathology, Kurume University School of Medicine, Kurume, Japan
| |
Collapse
|
24
|
Kawamoto K, Miyoshi H, Suzuki T, Kozai Y, Kato K, Miyahara M, Yujiri T, Choi I, Fujimaki K, Muta T, Kume M, Moriguchi S, Tamura S, Kato T, Tagawa H, Makiyama J, Kanisawa Y, Sasaki Y, Kurita D, Yamada K, Shimono J, Sone H, Takizawa J, Seto M, Kimura H, Ohshima K. A distinct subtype of Epstein-Barr virus-positive T/NK-cell lymphoproliferative disorder: adult patients with chronic active Epstein-Barr virus infection-like features. Haematologica 2017; 103:1018-1028. [PMID: 29242302 PMCID: PMC6058795 DOI: 10.3324/haematol.2017.174177] [Citation(s) in RCA: 34] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/06/2017] [Accepted: 12/06/2017] [Indexed: 12/14/2022] Open
Abstract
The characteristics of adult patients with chronic active Epstein-Barr virus infection are poorly recognized, hindering early diagnosis and an improved prognosis. We studied 54 patients with adult-onset chronic active Epstein-Barr virus infection diagnosed between 2005 and 2015. Adult onset was defined as an estimated age of onset of 15 years or older. To characterize the clinical features of these adults, we compared them to those of 75 pediatric cases (estimated age of onset <15 years). We compared the prognosis of adult-onset chronic active Epstein-Barr virus infection with that of patients with nasal-type (n=37) and non-nasal-type (n=45) extranodal NK/T-cell lymphoma. The median estimated age of onset of these lymphomas was 39 years (range, 16–86 years). Compared to patients with pediatric-onset disease, those in whom the chronic active Epstein-Barr virus infection developed in adulthood had a significantly decreased incidence of fever (P=0.005), but greater frequency of skin lesions (P<0.001). Moreover, hypersensitivity to mosquito bites and the occurrence of hydroa vacciniforme were less frequent in patients with adult-onset disease (P<0.001 and P=0.0238, respectively). Thrombocytopenia, high Epstein-Barr virus nuclear antigen antibody titer, and the presence of hemophagocytic syndrome were associated with a poor prognosis (P=0.0087, P=0.0236, and P=0.0149, respectively). Allogeneic hematopoietic stem cell transplantation may improve survival (P=0.0289). Compared to pediatric-onset chronic active Epstein-Barr virus infection and extranodal NK/T-cell lymphoma, adult-onset chronic active Epstein-Barr virus infection had a poorer prognosis (P<0.001 and P=0.0484, respectively). Chronic active Epstein-Barr virus infection can develop in a wide age range, with clinical differences between adult-onset and pediatric-onset disease. Adult-onset chronic active Epstein-Barr virus infection is a disease with a poor prognosis. Further research will be needed.
Collapse
Affiliation(s)
- Keisuke Kawamoto
- Department of Pathology, Kurume University School of Medicine, Niigata University, Japan.,Department of Hematology, Endocrinology and Metabolism, Faculty of Medicine, Niigata University, Japan
| | - Hiroaki Miyoshi
- Department of Pathology, Kurume University School of Medicine, Niigata University, Japan
| | - Takaharu Suzuki
- Department of Pathology, Kurume University School of Medicine, Niigata University, Japan.,Department of Hematology, Endocrinology and Metabolism, Faculty of Medicine, Niigata University, Japan
| | - Yasuji Kozai
- Department of Hematology, Tokyo Metropolitan Tama Medical Center, Fuchu, Japan
| | - Koji Kato
- Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan
| | | | - Toshiaki Yujiri
- Third Department of Internal Medicine, Yamaguchi University School of Medicine, Ube, Japan
| | - Ilseung Choi
- Department of Hematology, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan
| | | | - Tsuyoshi Muta
- Department of Hematology, Japan Community Health Care Organization Kyushu Hospital, Japan
| | - Masaaki Kume
- Department of Hematology, Hiraka General Hospital, Yokote, Japan
| | | | - Shinobu Tamura
- Department of Hematology and Oncology, Wakayama Medical University, Japan
| | - Takeharu Kato
- Department of Hematology, Sasebo City General Hospital, Japan
| | - Hiroyuki Tagawa
- Department of Hematology, Nephrology, and Rheumatology, Akita University Graduate School of Medicine, Japan
| | - Junya Makiyama
- Department of Hematology, National Hospital Organization Nagasaki Medical Center, Omura, Japan
| | - Yuji Kanisawa
- Department of Hematology and Oncology, Oji General Hospital, Tomakomai, Japan
| | - Yuya Sasaki
- Department of Pathology, Kurume University School of Medicine, Niigata University, Japan
| | - Daisuke Kurita
- Department of Pathology, Kurume University School of Medicine, Niigata University, Japan
| | - Kyohei Yamada
- Department of Pathology, Kurume University School of Medicine, Niigata University, Japan
| | - Joji Shimono
- Department of Pathology, Kurume University School of Medicine, Niigata University, Japan
| | - Hirohito Sone
- Department of Hematology, Endocrinology and Metabolism, Faculty of Medicine, Niigata University, Japan
| | - Jun Takizawa
- Department of Hematology, Endocrinology and Metabolism, Faculty of Medicine, Niigata University, Japan
| | - Masao Seto
- Department of Pathology, Kurume University School of Medicine, Niigata University, Japan
| | - Hiroshi Kimura
- Department of Virology, Faculty of Medicine, Nagoya University, Japan
| | - Koichi Ohshima
- Department of Pathology, Kurume University School of Medicine, Niigata University, Japan
| |
Collapse
|
25
|
Shimono J, Miyoshi H, Kato T, Sugio T, Miyawaki K, Kamimura T, Miyagishima T, Eto T, Imaizumi Y, Kato K, Nagafuji K, Akashi K, Seto M, Teshima T, Ohshima K. Hepatitis C virus infection is an independent prognostic factor in follicular lymphoma. Oncotarget 2017; 9:1717-1725. [PMID: 29416725 PMCID: PMC5788593 DOI: 10.18632/oncotarget.23138] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/23/2017] [Accepted: 11/13/2017] [Indexed: 01/08/2023] Open
Abstract
Hepatitis C virus (HCV) is a single-stranded RNA virus that not only affects hepatocytes, by B cells as well. It is thought that HCV is involved in the onset of B-cell lymphoma. The clinicopathological characteristics of HCV-positive diffuse large B-cell lymphoma (DLBCL) and HCV-positive splenic marginal zone lymphoma (SMZL) are known, but there has been no report on HCV-positive follicular lymphoma (FL). In this study, the clinicopathological characteristics of HCV-positive FL were examined in 263 patients with FL who were classified into a HCV-positive group with HCV antibody and negative groups without one. The number of patients with HCV-positive FL and HCV-negative FL was 10 (3.8%) and 253 (96.2%), respectively. The patients with HCV-positive FL commonly had more than one region of lymphadenopathy, Ann Arbor stage III/IV, hemoglobin <120 g/l, elevated lactate dehydrogenase level, and high-risk categorization of Follicular Lymphoma International Prognostic Index (FLIPI) than in patients with HCV-negative FL. Overall survival and progression-free survival were poorer in patients with HCV-positive FL than in those with HCV-negative FL (p < 0.0001 and 0.006, respectively). Also, multivariate analysis revealed that positive HCV antibody was a poor prognostic factor of OS. In conclusion, HCV-positive FL has unique clinical features and may have a great impact on the overall survival of affected patients.
Collapse
Affiliation(s)
- Joji Shimono
- Department of Pathology, Kurume University, School of Medicine, Kurume, Japan.,Department of Hematology, Hokkaido University Faculty of Medicine, Sapporo, Japan
| | - Hiroaki Miyoshi
- Department of Pathology, Kurume University, School of Medicine, Kurume, Japan
| | - Takeharu Kato
- Department of Hematology, Sasebo City General Hospital, Sasebo, Japan.,Department of Hematology, Atomic Bomb Disease and Hibakusha Medicine Unit, Atomic Bomb Disease Institute, Nagasaki University, Nagasaki, Japan
| | - Takeshi Sugio
- Department of Medicine and Biosystemic Science, Kyushu University Faculty of Medicine, Fukuoka, Japan
| | - Kohta Miyawaki
- Department of Medicine and Biosystemic Science, Kyushu University Faculty of Medicine, Fukuoka, Japan
| | | | | | - Tetsuya Eto
- Department of Hematology, Hamanomachi Hospital, Fukuoka, Japan
| | - Yoshitaka Imaizumi
- Department of Hematology, Atomic Bomb Disease and Hibakusha Medicine Unit, Atomic Bomb Disease Institute, Nagasaki University, Nagasaki, Japan
| | - Koji Kato
- Department of Medicine and Biosystemic Science, Kyushu University Faculty of Medicine, Fukuoka, Japan
| | - Koji Nagafuji
- Department of Hematology, Kurume University, School of Medicine, Kurume, Japan
| | - Koichi Akashi
- Department of Medicine and Biosystemic Science, Kyushu University Faculty of Medicine, Fukuoka, Japan
| | - Masao Seto
- Department of Pathology, Kurume University, School of Medicine, Kurume, Japan
| | - Takanori Teshima
- Department of Hematology, Hokkaido University Faculty of Medicine, Sapporo, Japan
| | - Koichi Ohshima
- Department of Pathology, Kurume University, School of Medicine, Kurume, Japan
| |
Collapse
|
26
|
Kawamoto K, Miyoshi H, Suzuki T, Sasaki Y, Yamada K, Yanagida E, Muto R, Kiryu M, Sone H, Seto M, Ohshima K, Takizawa J. Frequent expression of CD30 in extranodal NK/T-cell lymphoma: Potential therapeutic target for anti-CD30 antibody-based therapy. Hematol Oncol 2017; 36:166-173. [DOI: 10.1002/hon.2482] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/21/2017] [Revised: 09/16/2017] [Accepted: 09/21/2017] [Indexed: 12/14/2022]
Affiliation(s)
- Keisuke Kawamoto
- Department of Hematology, Endocrinology and Metabolism, Faculty of Medicine; Niigata University; Niigata Japan
- Department of Pathology; Kurume University School of Medicine; Kurume Japan
| | - Hiroaki Miyoshi
- Department of Pathology; Kurume University School of Medicine; Kurume Japan
| | - Takaharu Suzuki
- Department of Hematology, Endocrinology and Metabolism, Faculty of Medicine; Niigata University; Niigata Japan
| | - Yuya Sasaki
- Department of Pathology; Kurume University School of Medicine; Kurume Japan
| | - Kyohei Yamada
- Department of Pathology; Kurume University School of Medicine; Kurume Japan
| | - Eriko Yanagida
- Department of Pathology; Kurume University School of Medicine; Kurume Japan
| | - Reiji Muto
- Department of Pathology; Kurume University School of Medicine; Kurume Japan
| | - Maiko Kiryu
- Department of Hematology, Endocrinology and Metabolism, Faculty of Medicine; Niigata University; Niigata Japan
| | - Hirohito Sone
- Department of Hematology, Endocrinology and Metabolism, Faculty of Medicine; Niigata University; Niigata Japan
| | - Masao Seto
- Department of Pathology; Kurume University School of Medicine; Kurume Japan
| | - Koichi Ohshima
- Department of Pathology; Kurume University School of Medicine; Kurume Japan
| | - Jun Takizawa
- Department of Hematology, Endocrinology and Metabolism, Faculty of Medicine; Niigata University; Niigata Japan
| |
Collapse
|
27
|
Shimono J, Miyoshi H, Kamimura T, Eto T, Miyagishima T, Sasaki Y, Kurita D, Kawamoto K, Nagafuji K, Seto M, Teshima T, Ohshima K. Clinicopathological features of primary splenic follicular lymphoma. Ann Hematol 2017; 96:2063-2070. [PMID: 28975390 DOI: 10.1007/s00277-017-3139-y] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/21/2017] [Accepted: 09/19/2017] [Indexed: 12/21/2022]
Abstract
Follicular lymphoma (FL) is a low-grade lymphoma that is usually characterized by generalized lymphadenopathy. Extranodal invasion by FL generally involves the bone marrow, skin, and duodenum; splenic infiltration often occurs in the advanced stages. However, primary splenic FL is very rare. Hence, few studies have been performed on splenic FL, and its clinicopathological features have not been established. This study aimed to investigate the clinicopathological features of primary splenic FL, as compared to nodal FL. We analyzed 17 patients diagnosed with primary splenic FL and 153 control patients with systemic FL. Hepatitis C virus (HCV)-positive status was significantly more common in patients with splenic FL than in the control patients (p = 0.02). Ann Arbor stage III or IV (p = 0.0003) and high-risk FLIPI (Follicular Lymphoma International Prognostic Index) (p = 0.03) were significantly less common in patients with splenic FL than in the control patients; however, the overall and progression-free survival curves were not significantly different between the groups. Among the 17 patients with splenic FL, the progression-free survival was significantly worse in patients who underwent splenectomy without receiving postoperative chemotherapy than in those who did (p = 0.03). These results suggest that primary splenic FL should be considered different from systemic FL; accordingly, its management should also be conducted differently.
Collapse
Affiliation(s)
- Joji Shimono
- Department of Pathology, School of Medicine, Kurume University, 67, Asahi-machi, Kurume, 830-0011, Japan.,Department of Hematology, Hokkaido University Graduate School of Medicine, Sapporo, Japan
| | - Hiroaki Miyoshi
- Department of Pathology, School of Medicine, Kurume University, 67, Asahi-machi, Kurume, 830-0011, Japan.
| | | | - Tetsuya Eto
- Department of Hematology, Hamanomachi Hospital, Fukuoka, Japan
| | | | - Yuya Sasaki
- Department of Pathology, School of Medicine, Kurume University, 67, Asahi-machi, Kurume, 830-0011, Japan
| | - Daisuke Kurita
- Department of Pathology, School of Medicine, Kurume University, 67, Asahi-machi, Kurume, 830-0011, Japan
| | - Keisuke Kawamoto
- Department of Pathology, School of Medicine, Kurume University, 67, Asahi-machi, Kurume, 830-0011, Japan
| | - Koji Nagafuji
- Department of Hematology, School of Medicine, Kurume University, Kurume, Japan
| | - Masao Seto
- Department of Pathology, School of Medicine, Kurume University, 67, Asahi-machi, Kurume, 830-0011, Japan
| | - Takanori Teshima
- Department of Hematology, Hokkaido University Graduate School of Medicine, Sapporo, Japan
| | - Koichi Ohshima
- Department of Pathology, School of Medicine, Kurume University, 67, Asahi-machi, Kurume, 830-0011, Japan
| |
Collapse
|
28
|
Kato T, Miyoshi H, Kobayashi S, Yoshida N, Imaizumi Y, Seto M, Uchimaru K, Miyazaki Y, Ohshima K. Clinicopathological analysis in PTCL-NOS with CADM1 expression. Virchows Arch 2017; 471:659-666. [DOI: 10.1007/s00428-017-2233-9] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/01/2017] [Revised: 08/24/2017] [Accepted: 09/13/2017] [Indexed: 01/09/2023]
|
29
|
Kagami Y, Uchiyama S, Kato H, Okada Y, Seto M, Kinoshita T. Establishment of cell lines from adult T-cell leukemia cells dependent on negatively charged polymers. J Clin Exp Hematop 2017; 57:9-14. [PMID: 28420813 DOI: 10.3960/jslrt.16021] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022] Open
Abstract
Growing adult T-cell leukemia/lymphoma (ATLL) cells in vitro is difficult. Here, we examined the effects of static electricity in the culture medium on the proliferation of ATLL cells. Six out of 10 ATLL cells did not proliferate in vitro and thus had to be cultured in a medium containing negatively charged polymers. In the presence of poly-γ-glutamic acid (PGA) or chondroitin sulfate (CDR), cell lines (HKOX3-PGA, HKOX3-CDR) were established from the same single ATLL case using interleukin (IL)-2, IL-4, and feeder cells expressing OX40L (OX40L+HK). Dextran sulfate inhibited growth in both HKOX3 cell lines. Both PGA and OX40L+HK were indispensable for HKOX3-PGA growth, but HKOX3-CDR could proliferate in the presence of CDR or OX40L+HK alone. Thus, the specific action of each negatively charged polymer promoted the growth of specific ATLL cells in vitro.
Collapse
Affiliation(s)
| | - Susumu Uchiyama
- Department of Biotechnology, Graduate School of Engineering, Osaka University
| | - Harumi Kato
- Department of Hematology and Cell Therapy, Aichi Cancer Center Hospital
| | - Yasutaka Okada
- Department of Clinical Laboratories, Aichi Cancer Center Hospital
| | - Masao Seto
- Department of Pathology, Kurume University School of Medicine
| | | |
Collapse
|
30
|
Sasaki Y, Seto M, Miyoshi H, Okada S, Yokoyama S, Ohshima A, Ohshima K. Papillary thyroid carcinoma expressing CD20. Pathol Int 2017; 67:350-354. [PMID: 28618063 DOI: 10.1111/pin.12548] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/28/2016] [Accepted: 05/11/2017] [Indexed: 11/28/2022]
Abstract
We identified a case of lymphadenopathy of metastatic papillary thyroid carcinoma (PTC) with CD20 expression, which was also expressed by the primary tumor. CD20 expression was identified using immunohistochemistry (IHC) in metastatic PTC biopsy samples from a 58-year-old woman. CD20 expression was initially determined using a CD20-recognizing L26 clone. To validate this phenomenon, we performed IHC with another antibody that recognizes the N-terminus of CD20 and fluorescent double staining using anti-TTF-1 and anti-CD20 antibodies. Taken together, we concluded metastatic PTC expressed CD20. We also examined 21 additional PTC cases and found four more cases that were CD20 positive. Therefore, five of the 22 (23%) cases were positive for CD20. In the positive cases, four cases were classical papillary thyroid carcinoma and one case was a follicular variant of papillary thyroid carcinoma. CD20 is an important target for molecularly targeted therapy for a subset of B-cell lymphomas. Complement-dependent and antibody-dependent cellular cytotoxicities are important effector mechanisms of anti-CD20 therapy. Here, for the first time, we report PTC with expression of CD20. Our findings provide a rationale for treating CD20-positive PTC patients with anti-CD20 therapy.
Collapse
Affiliation(s)
- Yuya Sasaki
- Department of Pathology, Kurume University School of Medicine, Fukuoka, Japan
| | - Masao Seto
- Department of Pathology, Kurume University School of Medicine, Fukuoka, Japan
| | - Hiroaki Miyoshi
- Department of Pathology, Kurume University School of Medicine, Fukuoka, Japan
| | - Shinya Okada
- Department of Pathology, International University of Health and Welfare Hospital, Tochigi, Japan
| | - Shintaro Yokoyama
- Department of Pathology, Kurume University School of Medicine, Fukuoka, Japan.,Department of Surgery, Kurume University School of Medicine, Fukuoka, Japan
| | | | - Koichi Ohshima
- Department of Pathology, Kurume University School of Medicine, Fukuoka, Japan
| |
Collapse
|
31
|
Kawamoto K, Miyoshi H, Suzuki T, Muto R, Yamada K, Yanagida E, Koshino M, Sasaki Y, Takizawa J, Sone H, Sugita Y, Seto M, Ohshima K. Clinicopathological features of cryptococcal lymphadenitis and a review of literature. J Clin Exp Hematop 2017; 57:26-30. [PMID: 28592745 DOI: 10.3960/jslrt.17011] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022] Open
Abstract
Cryptococcosis is an invasive fungal infection in immunocompromised patients. The clinicopathological characteristics of cryptococcal lymphadenitis are not well known. We analyzed three cases of cryptococcal lymphadenitis and compared their characteristics with those in previous reports. Two patients were human immunodeficiency virus (HIV) carriers, and one patient was a human T-cell leukemia virus type-1 (HTLV-1) carrier. The age of the HTLV-1 carrier with cryptococcosis was much higher than that of the HIV-1 carriers. CD4-positive cell counts in peripheral blood were 5.8/μL (Case 1) and 79.9/μL (Case 2) in the HIV carriers and 3285/μL in the HTLV-1 carrier (Case 3). According to flow cytometric analysis of the lymph nodes of Cases 1, 2, and 3, 50.0%, 87.1%, and 85.9%, respectively, of the T-cells were CD3; 9.8%, 16.3%, and 75.8%, respectively, were CD4; and 35.5%, 77.3%, and 10.2%, respectively, were CD8. Cryptococcus neoformans was detected in tissue culture in all patients. Although gelatinous lesions and numerous fungal cocci were observed in the two HIV patients, the granuloma formation was small. Gelatinous formation and granuloma formation were observed in the HTLV-1 carrier. Necrosis was observed in all cases. In previous reports, granuloma formation, epithelioid cells, and necrotic lesions were observed in most cases. Most of the patients were also immunosuppressed. However, no HTLV-1 carrier was detected. In conclusion, lymphadenopathy in a HTLV-1 carrier may suggest the presence of cryptococcal lymphadenitis. The frequency of cryptococcosis in HTVL-1 carriers may increase with increase in the long-term survival rate of HTLV-1 carriers.
Collapse
Affiliation(s)
- Keisuke Kawamoto
- Department of Hematology, Endocrinology and Metabolism, Faculty of Medicine, Niigata University.,Department of Pathology, School of Medicine, Kurume University
| | - Hiroaki Miyoshi
- Department of Pathology, School of Medicine, Kurume University
| | - Takaharu Suzuki
- Department of Hematology, Endocrinology and Metabolism, Faculty of Medicine, Niigata University
| | - Reiji Muto
- Department of Pathology, School of Medicine, Kurume University
| | - Kyohei Yamada
- Department of Pathology, School of Medicine, Kurume University
| | - Eriko Yanagida
- Department of Pathology, School of Medicine, Kurume University
| | - Mayuko Koshino
- Department of Pathology, School of Medicine, Kurume University
| | - Yuya Sasaki
- Department of Pathology, School of Medicine, Kurume University
| | - Jun Takizawa
- Department of Hematology, Endocrinology and Metabolism, Faculty of Medicine, Niigata University
| | - Hirohito Sone
- Department of Hematology, Endocrinology and Metabolism, Faculty of Medicine, Niigata University
| | - Yasuo Sugita
- Department of Pathology, School of Medicine, Kurume University
| | - Masao Seto
- Department of Pathology, School of Medicine, Kurume University
| | - Koichi Ohshima
- Department of Pathology, School of Medicine, Kurume University
| |
Collapse
|
32
|
Kawamoto K, Miyoshi H, Sasaki Y, Kurita D, Yamada K, Shimono J, Sone H, Takizawa J, Seto M, Kimura H, Ohshima K. ADULT PATIENTS WITH CAEBV-LIKE FEATURES: A DISTINCT SUBTYPE OF EPSTEIN-BARR VIRUS POSITIVE T/NK-CELL LYMPHOPROLIFERATIVE DISORDER. Hematol Oncol 2017. [DOI: 10.1002/hon.2437_27] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- K. Kawamoto
- Pathology; Kurume University School Of Medicine; Kurume Japan
| | - H. Miyoshi
- Pathology; Kurume University School Of Medicine; Kurume Japan
| | - Y. Sasaki
- Pathology; Kurume University School Of Medicine; Kurume Japan
| | - D. Kurita
- Pathology; Kurume University School Of Medicine; Kurume Japan
| | - K. Yamada
- Pathology; Kurume University School Of Medicine; Kurume Japan
| | - J. Shimono
- Pathology; Kurume University School Of Medicine; Kurume Japan
| | - H. Sone
- Hematology, Endocrinology, and Metabolism; Niigata University Faculty of Medicine; Niigata Japan
| | - J. Takizawa
- Hematology, Endocrinology, and Metabolism; Niigata University Faculty of Medicine; Niigata Japan
| | - M. Seto
- Pathology; Kurume University School Of Medicine; Kurume Japan
| | - H. Kimura
- Virology; Nagoya University Graduate School of Medicine; Nagoya Japan
| | - K. Ohshima
- Pathology; Kurume University School Of Medicine; Kurume Japan
| |
Collapse
|
33
|
Masuda T, Okubo S, Hara H, Hiraki T, Kitao S, Miyamoto Y, Okai K, Ozaki R, Sasao N, Seto M, Uetake S, Yamaguchi A, Yoda Y, Yoshimi A, Yoshimura K. Fast x-ray detector system with simultaneous measurement of timing and energy for a single photon. Rev Sci Instrum 2017; 88:063105. [PMID: 28667968 DOI: 10.1063/1.4989405] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/07/2023]
Abstract
We developed a fast X-ray detector system for nuclear resonant scattering (NRS) experiments. Our system employs silicon avalanche photo-diode (Si-APD) as a fast X-ray sensor. The system is able to acquire both timing and energy of a single X-ray photon simultaneously in a high rate condition, 106 counts per second for one Si-APD. The performance of the system was investigated in SPring-8, a synchrotron radiation facility in Japan. Good time resolution of 120 ps (FWHM) was achieved with a slight tail distribution in the time spectrum by a level of 10-9 at 1 ns apart from the peak. Using this system, we successfully observed the NRS from the 26.27-keV level of mercury-201, which has a half-life of 630(50) ps. We also demonstrated the reduction of background events caused by radioactive decays in a radioactive sample by discriminating photon energy.
Collapse
Affiliation(s)
- T Masuda
- Research Institute for Interdisciplinary Science, Okayama University, Okayama 700-8530, Japan
| | - S Okubo
- Graduate School of Natural Science and Technology, Okayama University, Okayama 700-8530, Japan
| | - H Hara
- Research Institute for Interdisciplinary Science, Okayama University, Okayama 700-8530, Japan
| | - T Hiraki
- Research Institute for Interdisciplinary Science, Okayama University, Okayama 700-8530, Japan
| | - S Kitao
- Research Reactor Institute, Kyoto University, Osaka 590-0494, Japan
| | - Y Miyamoto
- Research Institute for Interdisciplinary Science, Okayama University, Okayama 700-8530, Japan
| | - K Okai
- Graduate School of Natural Science and Technology, Okayama University, Okayama 700-8530, Japan
| | - R Ozaki
- Graduate School of Natural Science and Technology, Okayama University, Okayama 700-8530, Japan
| | - N Sasao
- Research Institute for Interdisciplinary Science, Okayama University, Okayama 700-8530, Japan
| | - M Seto
- Research Reactor Institute, Kyoto University, Osaka 590-0494, Japan
| | - S Uetake
- Research Institute for Interdisciplinary Science, Okayama University, Okayama 700-8530, Japan
| | - A Yamaguchi
- Quantum Metrology Laboratory, RIKEN, Saitama 351-0198, Japan
| | - Y Yoda
- Japan Synchrotron Radiation Research Institute, Hyogo 679-5198, Japan
| | - A Yoshimi
- Research Institute for Interdisciplinary Science, Okayama University, Okayama 700-8530, Japan
| | - K Yoshimura
- Research Institute for Interdisciplinary Science, Okayama University, Okayama 700-8530, Japan
| |
Collapse
|
34
|
Kawamoto K, Miyoshi H, Yanagida E, Yoshida N, Kiyasu J, Kozai Y, Morikita T, Kato T, Suzushima H, Tamura S, Muta T, Kato K, Eto T, Seki R, Nagafuji K, Sone H, Takizawa J, Seto M, Ohshima K. Comparison of clinicopathological characteristics between T-cell prolymphocytic leukemia and peripheral T-cell lymphoma, not otherwise specified. Eur J Haematol 2017; 98:459-466. [DOI: 10.1111/ejh.12856] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 01/22/2017] [Indexed: 12/25/2022]
Affiliation(s)
- Keisuke Kawamoto
- Department of Pathology; School of Medicine; Kurume University; Kurume Japan
- Department of Hematology, Endocrinology, and Metabolism; Faculty of Medicine; Niigata University; Niigata Japan
| | - Hiroaki Miyoshi
- Department of Pathology; School of Medicine; Kurume University; Kurume Japan
| | - Eriko Yanagida
- Department of Pathology; School of Medicine; Kurume University; Kurume Japan
| | - Noriaki Yoshida
- Department of Pathology; School of Medicine; Kurume University; Kurume Japan
| | | | - Yasuji Kozai
- Department of Hematology; Tokyo Metropolitan Tama Medical Center; Fuchu Japan
| | - Tatsuma Morikita
- Division of Medical Oncology; Saiseikai Kumamoto Hospital; Kumamoto Japan
| | - Takeharu Kato
- Department of Hematology; Sasebo City General Hospital; Sasebo Japan
| | - Hitoshi Suzushima
- Department of Hematology; Kumamoto Shinto General Hospital; Kumamoto Japan
| | - Shinobu Tamura
- Department of Hematology and Oncology; Wakayama Medical University; Wakayama Japan
| | - Tsuyoshi Muta
- Department of Hematology; Japan Community Health Care Organization Kyushu Hospital; Kitakyushu Japan
| | - Koji Kato
- Department of Medicine and Biosystemic Science; Kyushu University Graduate School of Medical Sciences; Fukuoka Japan
| | - Tetsuya Eto
- Department of Hematology; Hamanomachi Hospital; Fukuoka Japan
| | - Ritsuko Seki
- Department of Hematology and Oncology; School of Medicine; Kurume University; Kurume Japan
| | - Koji Nagafuji
- Department of Hematology and Oncology; School of Medicine; Kurume University; Kurume Japan
| | - Hirohito Sone
- Department of Hematology, Endocrinology, and Metabolism; Faculty of Medicine; Niigata University; Niigata Japan
| | - Jun Takizawa
- Department of Hematology, Endocrinology, and Metabolism; Faculty of Medicine; Niigata University; Niigata Japan
| | - Masao Seto
- Department of Pathology; School of Medicine; Kurume University; Kurume Japan
| | - Koichi Ohshima
- Department of Pathology; School of Medicine; Kurume University; Kurume Japan
| |
Collapse
|
35
|
Shimono J, Miyoshi H, Seto M, Teshima T, Ohshima K. Clinical features of diffuse large B-cell lymphoma with polyploidy. Pathol Int 2016; 67:17-23. [PMID: 27868293 DOI: 10.1111/pin.12478] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/04/2016] [Revised: 10/13/2016] [Accepted: 10/25/2016] [Indexed: 11/30/2022]
Abstract
Polyploidy, defined as more than two sets of homologous chromosomes, is found in a variety of malignant tumors and is thought to be related to disease pathogenesis. However, there have been no studies that have investigated polyploidy in diffuse large B-cell lymphoma (DLBCL). Here we reviewed clinicopathological features of 16 cases of DLBCL with polypoidy, which was defined as DLBCL with either near-tetraploid or greater number of chromosomes as detected by the G-band method. The frequency of polyploid DLBCL was 2.9 % (16/544), including 15 near-tetraploid and one near-pentaploid case. CD5, CD30 and EBER positive cases were 13 % (2/16), 13 % (2/16) and 6 % (1/16), respectively. Bcl2 positive cases were 75 % (12/16). The numbers of huge and multinucleated cells were higher in polyploid than in non-polyploid DLBCL (P = 0.0029 and P < 0.0001, respectively). Clinical features of polyploid DLBCL included reduced infiltration of extranodal sites (2/15, 13 %) and major lymph node infiltration. Of seven cases that received chemotherapy, six responded to treatment and survived. Our results suggest that polyploid DLBCL represents a clinicopathologically characteristic group of DLBCL. This knowledge can be useful for informing more personalized and targeted management of DLBCL patients.
Collapse
Affiliation(s)
- Joji Shimono
- Department of Pathology, Kurume University, School of Medicine, Kurume, Japan.,Department of Hematology, Hokkaido University Graduate School of Medicine, Sapporo, Japan
| | - Hiroaki Miyoshi
- Department of Pathology, Kurume University, School of Medicine, Kurume, Japan
| | - Masao Seto
- Department of Pathology, Kurume University, School of Medicine, Kurume, Japan
| | - Takanori Teshima
- Department of Hematology, Hokkaido University Graduate School of Medicine, Sapporo, Japan
| | - Koichi Ohshima
- Department of Pathology, Kurume University, School of Medicine, Kurume, Japan
| |
Collapse
|
36
|
Takahara T, Matsuo K, Seto M, Nakamura S, Tsuzuki S. Synergistic activity of Card11 mutant and Bcl6 in the development of diffuse large B-cell lymphoma in a mouse model. Cancer Sci 2016; 107:1572-1580. [PMID: 27560392 PMCID: PMC5132338 DOI: 10.1111/cas.13057] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/16/2016] [Revised: 08/05/2016] [Accepted: 08/13/2016] [Indexed: 12/17/2022] Open
Abstract
Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of malignant lymphoma; it derives from germinal center B cells. Although DLBCL harbors many genetic alterations, synergistic roles between such alterations in the development of lymphoma are largely undefined. We previously established a mouse model of lymphoma by transplanting gene-transduced germinal center B cells into mice. Here, we chose one of the frequently mutated genes in DLBCL, Card11 mutant, to explore its possible synergy with other genes, using our lymphoma model. Given that BCL6 and BCL2 expression and/or function are often deregulated in human lymphoma, we examined the possible synergy between Card11, Bcl6, and Bcl2. Germinal center B cells were induced in vitro, transduced with Card11 mutant, Bcl6, and Bcl2, and transplanted. Mice rapidly developed lymphomas, with exogenously transduced Bcl2 being dispensable. Although some mice developed lymphoma in the absence of transduced Bcl6, the absence was compensated by elevated expression of endogenous Bcl6. Additionally, the synergy between Card11 mutant and Bcl6 in the development of lymphoma was confirmed by the fact that the combination of Card11 mutant and Bcl6 caused lymphoma or death significantly earlier and with higher penetrance than Card11 mutant or Bcl6 alone. Lymphoma cells expressed interferon regulatory factor 4 and PR domain 1, indicating their differentiation toward plasmablasts, which characterize activated B cell-like DLBCL that represents a clinically aggressive subtype in humans. Thus, our mouse model provides a versatile tool for studying the synergistic roles of altered genes underlying lymphoma development.
Collapse
Affiliation(s)
- Taishi Takahara
- Division of Molecular Medicine, Aichi Cancer Center, Research Institute, Nagoya, Japan.,Department of Pathology and Clinical Laboratory, Nagoya University Hospital, Nagoya, Japan.,Department of Surgical Pathology, Aichi Medical University Hospital, Nagakute, Japan
| | - Keitaro Matsuo
- Division of Molecular Medicine, Aichi Cancer Center, Research Institute, Nagoya, Japan
| | - Masao Seto
- Department of Pathology, Kurume University School of Medicine, Kurume, Japan
| | - Shigeo Nakamura
- Department of Pathology and Clinical Laboratory, Nagoya University Hospital, Nagoya, Japan
| | - Shinobu Tsuzuki
- Division of Molecular Medicine, Aichi Cancer Center, Research Institute, Nagoya, Japan.,Department of Biochemistry, Aichi Medical University School of Medicine, Nagakute, Japan
| |
Collapse
|
37
|
Yonekura K, Tokunaga M, Kawakami N, Takeda K, Kanzaki T, Nakano N, Kubota A, Takeuchi S, Takatsuka Y, Seto M, Utsunomiya A. Cutaneous Adverse Reaction to Mogamulizumab May Indicate Favourable Prognosis in Adult T-cell Leukaemia-lymphoma. Acta Derm Venereol 2016; 96:1000-1002. [PMID: 27025906 DOI: 10.2340/00015555-2421] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
Affiliation(s)
- Kentaro Yonekura
- Department of dermatology, Imamura Bun-in Hospital, 8900064 Kagoshima, Japan.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
38
|
Tokunaga M, Uto H, Takeuchi S, Nakano N, Kubota A, Tokunaga M, Takatsuka Y, Seto M, Ido A, Utsunomiya A. Newly identified poor prognostic factors for adult T-cell leukemia–lymphoma treated with allogeneic hematopoietic stem cell transplantation. Leuk Lymphoma 2016; 58:37-44. [DOI: 10.1080/10428194.2016.1187270] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
39
|
Kakiuchi T, Takahara T, Kasugai Y, Arita K, Yoshida N, Karube K, Suguro M, Matsuo K, Nakanishi H, Kiyono T, Nakamura S, Osada H, Sekido Y, Seto M, Tsuzuki S. Modeling mesothelioma utilizing human mesothelial cells reveals involvement of phospholipase-C beta 4 in YAP-active mesothelioma cell proliferation. Carcinogenesis 2016; 37:1098-1109. [PMID: 27559111 DOI: 10.1093/carcin/bgw084] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/01/2016] [Revised: 07/13/2016] [Accepted: 08/06/2016] [Indexed: 12/17/2022] Open
Abstract
Mesotheliomas are frequently characterized by disruption of Hippo pathway due to deletion and/or mutation in genes, such as neurofibromin 2 ( NF2 ). Hippo disruption attenuates yes-associated protein (YAP) phosphorylation allowing YAP to translocate to the nucleus and regulate gene expression. The role of disrupted Hippo pathway in maintenance of established mesotheliomas has been extensively investigated using cell lines; however, its involvement in development of human mesothelioma has not been explored much. Here, we employed immortalized human mesothelial cells to disrupt Hippo pathway. YAP phosphorylation was reduced on NF2 knockdown and the cells exhibited altered growth in vitro , developing tumors when transplanted into nude mice. Similar results were obtained from enforced expression of wild-type or constitutively active (S127A) YAP, indicating the crucial role of activated YAP in the transformation of mesothelial cells. Gene expression analysis comparing control- and YAP-transduced immortalized human mesothelial cells revealed phospholipase-C beta 4 ( PLCB4 ) to be among the genes highly upregulated by YAP. PLCB4 was upregulated by YAP in immortalized human mesothelial cells and downregulated on YAP knockdown in Hippo-disrupted mesothelioma cell lines. PLCB4 knockdown attenuated the growth of YAP-transduced immortalized mesothelial cells and YAP-active, but not YAP-nonactive, mesothelioma cell lines. Our model system thus provides a versatile tool to investigate the mechanisms underlying mesothelioma development. We suggest that PLCB4 may be an attractive drug target for the treatment of mesothelioma.
Collapse
Affiliation(s)
- Tatsuo Kakiuchi
- Division of Molecular Medicine, Aichi Cancer Center Research Institute , Nagoya 464-8681 , Japan.,Department of Pathology and Clinical Laboratories, Nagoya University Hospital , Nagoya 466-0065 , Japan
| | - Taishi Takahara
- Division of Molecular Medicine, Aichi Cancer Center Research Institute , Nagoya 464-8681 , Japan.,Department of Pathology and Clinical Laboratories, Nagoya University Hospital , Nagoya 466-0065 , Japan
| | - Yumiko Kasugai
- Division of Molecular Medicine, Aichi Cancer Center Research Institute , Nagoya 464-8681 , Japan
| | - Kotaro Arita
- Third Department of Internal Medicine, Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama , Toyama 930-0194 , Japan
| | - Noriaki Yoshida
- Department of Pathology, Kurume University School of Medicine , Kurume 830-0011 , Japan.,Present address: Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
| | - Kennosuke Karube
- Laboratory of Cytopathology, Faculty of Medicine, University of the Ryukyus , Okinawa 903-0215 , Japan
| | - Miyuki Suguro
- Division of Molecular Medicine, Aichi Cancer Center Research Institute , Nagoya 464-8681 , Japan
| | - Keitaro Matsuo
- Division of Molecular Medicine, Aichi Cancer Center Research Institute , Nagoya 464-8681 , Japan
| | - Hayao Nakanishi
- Laboratory of Pathology and Clinical Research, Aichi Cancer Center , Aichi Hospital, Okazaki 444-0011 , Japan
| | - Tohru Kiyono
- Division of Carcinogenesis and Cancer Prevention, National Cancer Center Research Institute , Tokyo 104-0045 , Japan
| | - Shigeo Nakamura
- Department of Pathology and Clinical Laboratories, Nagoya University Hospital , Nagoya 466-0065 , Japan
| | - Hirotaka Osada
- Division of Molecular Oncology, Aichi Cancer Center Research Institute , Nagoya 464-8681 , Japan.,Department of Cancer Genetics, Program in Function Construction Medicine, Nagoya University Graduate School of Medicine , Nagoya 466-8550 , Japan and
| | - Yoshitaka Sekido
- Division of Molecular Oncology, Aichi Cancer Center Research Institute , Nagoya 464-8681 , Japan.,Department of Cancer Genetics, Program in Function Construction Medicine, Nagoya University Graduate School of Medicine , Nagoya 466-8550 , Japan and
| | - Masao Seto
- Department of Pathology, Kurume University School of Medicine , Kurume 830-0011 , Japan
| | - Shinobu Tsuzuki
- Division of Molecular Medicine, Aichi Cancer Center Research Institute , Nagoya 464-8681 , Japan.,Department of Biochemistry, Aichi Medical University School of Medicine , Nagakute, Aichi 480-1195 , Japan
| |
Collapse
|
40
|
Yoshida N, Miyoshi H, Kato T, Sakata-Yanagimoto M, Niino D, Taniguchi H, Moriuchi Y, Miyahara M, Kurita D, Sasaki Y, Shimono J, Kawamoto K, Utsunomiya A, Imaizumi Y, Seto M, Ohshima K. CCR4 frameshift mutation identifies a distinct group of adult T cell leukaemia/lymphoma with poor prognosis. J Pathol 2016; 238:621-6. [PMID: 26847489 DOI: 10.1002/path.4699] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/08/2015] [Revised: 01/06/2016] [Accepted: 01/29/2016] [Indexed: 12/12/2022]
Abstract
Adult T cell leukaemia/lymphoma (ATLL) is an intractable T cell neoplasm caused by human T cell leukaemia virus type 1. Next-generation sequencing-based comprehensive mutation studies have revealed recurrent somatic CCR4 mutations in ATLL, although clinicopathological findings associated with CCR4 mutations remain to be delineated. In the current study, 184 cases of peripheral T cell lymphoma, including 113 cases of ATLL, were subjected to CCR4 mutation analysis. This sequence analysis identified mutations in 27% (30/113) of cases of ATLL and 9% (4/44) of cases of peripheral T cell lymphoma not otherwise specified. Identified mutations included nonsense (NS) and frameshift (FS) mutations. No significant differences in clinicopathological findings were observed between ATLL cases stratified by presence of CCR4 mutation. All ATLL cases with CCR4 mutations exhibited cell-surface CCR4 positivity. Semi-quantitative CCR4 protein analysis of immunohistochemical sections revealed higher CCR4 expression in cases with NS mutations of CCR4 than in cases with wild-type (WT) CCR4. Furthermore, among ATLL cases, FS mutation was significantly associated with a poor prognosis, compared with NS mutation and WT CCR4. These results suggest that CCR4 mutation is an important determinant of the clinical course in ATLL cases, and that NS and FS mutations of CCR4 behave differently with respect to ATLL pathophysiology.
Collapse
Affiliation(s)
- Noriaki Yoshida
- Department of Pathology, Kurume University School of Medicine, Japan
| | - Hiroaki Miyoshi
- Department of Pathology, Kurume University School of Medicine, Japan
| | - Takeharu Kato
- Department of Pathology, Kurume University School of Medicine, Japan.,Department of Haematology, Atomic Bomb Disease and Hibakusha Medicine Unit, Atomic Bomb Disease Institute, Nagasaki University, Japan
| | | | - Daisuke Niino
- Department of Pathology, Kurume University School of Medicine, Japan
| | | | | | | | - Daisuke Kurita
- Department of Pathology, Kurume University School of Medicine, Japan
| | - Yuya Sasaki
- Department of Pathology, Kurume University School of Medicine, Japan
| | - Joji Shimono
- Department of Pathology, Kurume University School of Medicine, Japan
| | - Keisuke Kawamoto
- Department of Pathology, Kurume University School of Medicine, Japan
| | - Atae Utsunomiya
- Department of Haematology, Imamura Bun-in Hospital, Kagoshima, Japan
| | - Yoshitaka Imaizumi
- Department of Haematology, Atomic Bomb Disease and Hibakusha Medicine Unit, Atomic Bomb Disease Institute, Nagasaki University, Japan
| | - Masao Seto
- Department of Pathology, Kurume University School of Medicine, Japan
| | - Koichi Ohshima
- Department of Pathology, Kurume University School of Medicine, Japan
| |
Collapse
|
41
|
Kasugai Y, Yoshida N, Ohshima K, Matsuo K, Seto M, Tsuzuki S. New mouse model of acute adult T-cell leukemia generated by transplantation of AKT, BCLxL, and HBZ-transduced T cells. Cancer Sci 2016; 107:1072-8. [PMID: 27223899 PMCID: PMC4982588 DOI: 10.1111/cas.12974] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/23/2015] [Revised: 04/24/2016] [Accepted: 05/23/2016] [Indexed: 01/06/2023] Open
Abstract
Adult T‐cell leukemia/lymphoma (ATL) develops in human T‐cell leukemia virus type 1 (HTLV‐1) carriers. Although the HTLV‐1‐encoded HBZ gene is critically involved, HBZ alone is insufficient and additional, cooperative “hits” are required for the development of ATL. Candidate cooperative hits are being defined, but methods to rapidly explore their roles in ATL development in collaboration with HBZ are lacking. Here, we present a new mouse model of acute type ATL that can be generated rapidly by transplanting in vitro‐induced T cells that have been retrovirally transduced with HBZ and two cooperative genes, BCLxL and AKT, into mice. Co‐transduction of HBZ and BCLxL/AKT allowed these T cells to grow in vitro in the absence of cytokines (Flt3‐ligand and interleukin‐7), which did not occur with any two‐gene combination. Although transplanted T cells were a mixture of cells transduced with different combinations of the genes, tumors that developed in mice were composed of HBZ/BCLxL/AKT triply transduced T cells, showing the synergistic effect of the three genes. The genetic/epigenetic landscape of ATL has only recently been elucidated, and the roles of additional “hits” in ATL pathogenesis remain to be explored. Our model provides a versatile tool to examine the roles of these hits, in collaboration with HBZ, in the development of acute ATL.
Collapse
Affiliation(s)
- Yumiko Kasugai
- Division of Molecular Medicine, Aichi Cancer Center, Research Institute, Nagoya, Japan
| | - Noriaki Yoshida
- Department of Pathology, Kurume University School of Medicine, Kurume, Japan
| | - Koichi Ohshima
- Department of Pathology, Kurume University School of Medicine, Kurume, Japan
| | - Keitaro Matsuo
- Division of Molecular Medicine, Aichi Cancer Center, Research Institute, Nagoya, Japan
| | - Masao Seto
- Department of Pathology, Kurume University School of Medicine, Kurume, Japan
| | - Shinobu Tsuzuki
- Division of Molecular Medicine, Aichi Cancer Center, Research Institute, Nagoya, Japan
| |
Collapse
|
42
|
Sasaki Y, Guo Y, Arakawa F, Miyoshi H, Yoshida N, Koga Y, Nakashima K, Kurita D, Niino D, Seto M, Ohshima K. Analysis of the BRAFV600E mutation in 19 cases of Langerhans cell histiocytosis in Japan. Hematol Oncol 2016; 35:329-334. [PMID: 27041734 DOI: 10.1002/hon.2293] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/17/2015] [Revised: 01/20/2016] [Accepted: 02/11/2016] [Indexed: 01/31/2023]
Abstract
Langerhans cell histiocytosis (LCH) is a rare disease characterized by clonal proliferation of CD1a- and CD207 (langerin)-positive dendritic cells. Mutated BRAF (p.V600E) is observed in histiocyte-related diseases and dendritic cell-related diseases, including LCH. BRAFV600E is observed in some LCH cases and is thought to be involved in maintaining MAPK activation. We retrospectively analyzed BRAFV600E in 19 patients diagnosed with LCH. In our study, direct sequencing for exon 15, a mutation hotspot, demonstrated that 4 out of the 19 patients (21%) harbored a GTG > GAG (valine > glutamic acid) base substitution, which encodes BRAFV600E. The clinical impact of BRAFV600E in such diseases is unclear. The frequency of BRAFV600E in our LCH patients from Japan was lower than that reported in the United States and in Germany. However, reports from Asia tend to show a lower rate of the BRAFV600E mutation. These results imply the possibility of different genetic backgrounds in the pathogenesis of LCH across various ethnicities. We also performed an immunohistochemical analysis to detect BRAFV600E using the mutation-specific monoclonal antibody. However, immunohistochemical analysis failed to detect any mutated protein in any of the 4 BRAFV600E-positive cases. This implies that at present, BRAFV600E should be assessed by direct sequencing. Copyright © 2016 John Wiley & Sons, Ltd.
Collapse
Affiliation(s)
- Yuya Sasaki
- Department of Pathology, Kurume University School of Medicine, Kurume, Fukuoka, Japan
| | - Ying Guo
- Department of Pathology, Kurume University School of Medicine, Kurume, Fukuoka, Japan.,Department of Pathology, State Key Laboratory of Cancer Biology, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, China
| | - Fumiko Arakawa
- Department of Pathology, Kurume University School of Medicine, Kurume, Fukuoka, Japan
| | - Hiroaki Miyoshi
- Department of Pathology, Kurume University School of Medicine, Kurume, Fukuoka, Japan
| | - Noriaki Yoshida
- Department of Pathology, Kurume University School of Medicine, Kurume, Fukuoka, Japan
| | - Yuhki Koga
- Department of Pediatrics, Graduate School of Medical Sciences, Kyushu University, Kurume, Fukuoka, Japan
| | - Kazutaka Nakashima
- Department of Pathology, Kurume University School of Medicine, Kurume, Fukuoka, Japan
| | - Daisuke Kurita
- Department of Pathology, Kurume University School of Medicine, Kurume, Fukuoka, Japan
| | - Daisuke Niino
- Department of Pathology, Kurume University School of Medicine, Kurume, Fukuoka, Japan.,Department of Pathology, Nagasaki University, School of Medicine, Nagasaki, Japan
| | - Masao Seto
- Department of Pathology, Kurume University School of Medicine, Kurume, Fukuoka, Japan
| | - Koichi Ohshima
- Department of Pathology, Kurume University School of Medicine, Kurume, Fukuoka, Japan
| |
Collapse
|
43
|
Kai T, Tsukamoto Y, Hijiya N, Tokunaga A, Nakada C, Uchida T, Daa T, Iha H, Takahashi M, Nomura T, Sato F, Mimata H, Ikawa M, Seto M, Matsuura K, Moriyama M. Kidney-specific knockout ofSav1in the mouse promotes hyperproliferation of renal tubular epithelium through suppression of the Hippo pathway. J Pathol 2016; 239:97-108. [DOI: 10.1002/path.4706] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/28/2015] [Revised: 01/18/2016] [Accepted: 02/12/2016] [Indexed: 12/31/2022]
Affiliation(s)
- Tomoki Kai
- Department of Molecular Pathology, Faculty of Medicine; Oita University; Yufu Japan
- Department of Urology, Faculty of Medicine; Oita University; Yufu Japan
| | - Yoshiyuki Tsukamoto
- Department of Molecular Pathology, Faculty of Medicine; Oita University; Yufu Japan
| | - Naoki Hijiya
- Department of Molecular Pathology, Faculty of Medicine; Oita University; Yufu Japan
| | - Akinori Tokunaga
- Section of Physiology, Department of Integrative Aging Neuroscience; National Center for Geriatrics and Gerontology; Obu Japan
| | - Chisato Nakada
- Department of Molecular Pathology, Faculty of Medicine; Oita University; Yufu Japan
| | - Tomohisa Uchida
- Department of Molecular Pathology, Faculty of Medicine; Oita University; Yufu Japan
| | - Tsutomu Daa
- Department of Diagnostic Pathology, Faculty of Medicine; Oita University; Yufu Japan
| | - Hidekatsu Iha
- Department of Microbiology, Faculty of Medicine; Oita University; Yufu Japan
| | - Mika Takahashi
- Department of Molecular Pathology, Faculty of Medicine; Oita University; Yufu Japan
- Department of Urology, Faculty of Medicine; Oita University; Yufu Japan
| | - Takeo Nomura
- Department of Urology, Faculty of Medicine; Oita University; Yufu Japan
| | - Fuminori Sato
- Department of Urology, Faculty of Medicine; Oita University; Yufu Japan
| | - Hiromitsu Mimata
- Department of Urology, Faculty of Medicine; Oita University; Yufu Japan
| | - Masahito Ikawa
- Animal Resource Center for Infectious Diseases; Research Institute for Microbial Diseases; Suita Japan
| | - Masao Seto
- Division of Molecular Medicine; Aichi Cancer Institute; Nagoya Japan
| | - Keiko Matsuura
- Department of Molecular Pathology, Faculty of Medicine; Oita University; Yufu Japan
- Department of Biology, Faculty of Medicine; Oita University; Yufu Japan
| | - Masatsugu Moriyama
- Department of Molecular Pathology, Faculty of Medicine; Oita University; Yufu Japan
| |
Collapse
|
44
|
Shimada K, Shimada S, Sugimoto K, Nakatochi M, Suguro M, Hirakawa A, Hocking TD, Takeuchi I, Tokunaga T, Takagi Y, Sakamoto A, Aoki T, Naoe T, Nakamura S, Hayakawa F, Seto M, Tomita A, Kiyoi H. Development and analysis of patient-derived xenograft mouse models in intravascular large B-cell lymphoma. Leukemia 2016; 30:1568-79. [PMID: 27001523 DOI: 10.1038/leu.2016.67] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/22/2015] [Revised: 02/11/2016] [Accepted: 03/04/2016] [Indexed: 12/31/2022]
Abstract
Intravascular large B-cell lymphoma (IVLBCL) is a distinct disease entity with the peculiar characteristic that tumor cells proliferate within vessels. Despite recent advances in understanding the disease from clinical aspects, the underlying pathogenesis remains unknown. Here we demonstrate analyses of IVLBCL biology using four xenograft mouse models established from primary IVLBCL samples. In all four models, the main characteristic of IVLBCL tumor cell proliferation within vessels was retained. Time-lapse engraftment analyses revealed that the tumor cells initially engrafted and proliferated in the sinusoids and vessels in the liver and then engrafted and proliferated in multiple organs. Intriguingly, serial passage of tumor cells from the adrenal gland of a transplanted mouse developed from primary patient bone marrow cells into a second mouse showed that the tumor cells mainly distributed into the adrenal gland in the second mouse, implying the existence of clonal selection and/or evolution at engraftment of a specific organ. Gene expression profiling analyses demonstrated that the gene set associated with cell migration was enriched for normal peripheral blood B cells, indicating that inhibition of cell migration might be involved in IVLBCL pathogenesis. In conclusion, the mouse xenograft models described here are essential tools for uncovering IVLBCL biology.
Collapse
Affiliation(s)
- K Shimada
- Institute for Advanced Research, Nagoya University, Nagoya, Japan.,Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - S Shimada
- Department of Pathology and Clinical Laboratories, Nagoya University Hospital, Nagoya, Japan
| | - K Sugimoto
- Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan.,Fujii Memorial Research Institute, Otsuka Pharmaceutical Co., Ltd, Otsu, Japan
| | - M Nakatochi
- Center for Advanced Medicine and Clinical Research, Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - M Suguro
- Division of Molecular Medicine, Aichi Cancer Center Research Institute, Nagoya, Japan
| | - A Hirakawa
- Center for Advanced Medicine and Clinical Research, Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - T D Hocking
- Department of Human Genetics, McGill University, Montreal, Quebec, Canada
| | - I Takeuchi
- Department of Computer Science/Scientific and Engineering Simulation, Nagoya Institute of Technology, Nagoya, Japan
| | - T Tokunaga
- Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan.,Department of Hematology, National Hospital Organization, Nagoya Medical Center, Nagoya, Japan
| | - Y Takagi
- Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - A Sakamoto
- Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - T Aoki
- Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - T Naoe
- Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan.,Department of Hematology, National Hospital Organization, Nagoya Medical Center, Nagoya, Japan
| | - S Nakamura
- Department of Pathology and Clinical Laboratories, Nagoya University Hospital, Nagoya, Japan
| | - F Hayakawa
- Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - M Seto
- Division of Molecular Medicine, Aichi Cancer Center Research Institute, Nagoya, Japan.,Department of Pathology, Kurume University School of Medicine, Kurume, Japan
| | - A Tomita
- Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - H Kiyoi
- Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan
| |
Collapse
|
45
|
Hijiya N, Tsukamoto Y, Nakada C, Tung Nguyen L, Kai T, Matsuura K, Shibata K, Inomata M, Uchida T, Tokunaga A, Amada K, Shirao K, Yamada Y, Mori H, Takeuchi I, Seto M, Aoki M, Takekawa M, Moriyama M. Genomic Loss of DUSP4 Contributes to the Progression of Intraepithelial Neoplasm of Pancreas to Invasive Carcinoma. Cancer Res 2016; 76:2612-25. [DOI: 10.1158/0008-5472.can-15-1846] [Citation(s) in RCA: 30] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/08/2015] [Accepted: 02/14/2016] [Indexed: 11/16/2022]
|
46
|
Tokunaga M, Yoshida N, Nakano N, Kubota A, Takeuchi S, Takatsuka Y, Seto M, Utsunomiya A. Detection of an early adult T-cell leukemia-lymphoma clone in lymph nodes with anaplastic lymphoma kinase-negative anaplastic large cell lymphoma involvement. Cancer Genet 2016; 209:138-42. [PMID: 26874918 DOI: 10.1016/j.cancergen.2016.01.002] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/13/2015] [Revised: 11/22/2015] [Accepted: 01/22/2016] [Indexed: 10/22/2022]
Abstract
A 58-year-old man was admitted to our hospital with systemic lymphadenopathy and was diagnosed with anaplastic lymphoma kinase-negative anaplastic large cell lymphoma (ALCL) by lymph node biopsy. Although he was a human T-cell leukemia virus type I (HTLV-1) carrier, Southern blot analysis of the lymph node did not show monoclonal integration of HTLV-1 provirus deoxyribonucleic acid (DNA). He achieved complete remission after chemotherapy and subsequently, autologous peripheral blood stem cell transplantation (auto-PBSCT) was performed. Fifteen months after the auto-PBSCT, abnormal lymphocytes in the peripheral blood gradually increased. Southern blot analysis revealed monoclonal integration of HTLV-1 provirus DNA and monoclonal rearrangement of TRB. He was diagnosed with chronic type adult T-cell leukemia-lymphoma (ATL), which immediately progressed to the acute type. He died of tumor progression despite intensive chemotherapy. We analyzed genomic alterations of the ALCL and ATL cells using array comparative genomic hybridization. We found that the genomic alteration pattern differed between the two diseases. T-cell receptor clonality analysis using polymerase chain reaction (PCR) showed that the T-cell clone of the ATL was present in the lymph nodes with ALCL involvement, but not in peripheral blood. This finding suggests that lymph nodes can serve as a niche for ATL development.
Collapse
Affiliation(s)
- Masahito Tokunaga
- Department of Hematology, Imamura Bun-in Hospital, Kagoshima, Japan.
| | - Noriaki Yoshida
- Department of Pathology, Kurume University School of Medicine, Fukuoka, Japan
| | - Nobuaki Nakano
- Department of Hematology, Imamura Bun-in Hospital, Kagoshima, Japan
| | - Ayumu Kubota
- Department of Hematology, Imamura Bun-in Hospital, Kagoshima, Japan
| | - Shogo Takeuchi
- Department of Hematology, Imamura Bun-in Hospital, Kagoshima, Japan
| | | | - Masao Seto
- Department of Pathology, Kurume University School of Medicine, Fukuoka, Japan
| | - Atae Utsunomiya
- Department of Hematology, Imamura Bun-in Hospital, Kagoshima, Japan
| |
Collapse
|
47
|
Arakawa F, Kimura Y, Yoshida N, Miyoshi H, Doi A, Yasuda K, Nakajima K, Kiyasu J, Niino D, Sugita Y, Tashiro K, Kuhara S, Seto M, Ohshima K. Identification of miR-15b as a transformation-related factor in mantle cell lymphoma. Int J Oncol 2015; 48:485-92. [PMID: 26676972 PMCID: PMC4725451 DOI: 10.3892/ijo.2015.3295] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/15/2015] [Accepted: 11/24/2015] [Indexed: 12/12/2022] Open
Abstract
Mantle cell lymphoma (MCL) is an aggressive B cell lymphoma with a poor prognosis. It is characterized by the t(11;14)(q13;q32) translocation, resulting in overexpression of CCND1. Morphologically, MCL is categorised into two types: classical MCL (cMCL) and aggressive MCL (aMCL), with a proportion of cMCL progressing to develop into aMCL. miRNAs are currently considered to be important regulators for cell behavior and are deregulated in many malignancies. Although several genetic alterations have been implicated in the transformation of cMCL to aMCL, the involvement of miRNAs in transformation is not known. In an effort to identify the miRNAs related to the transformation of MCL, miRNA microarray analyses were used for cMCL and aMCL cases. These analyses demonstrated significant differences in the expression of seven microRNAs based on a t-test (p-value <0.05); miR-15b was greatly upregulated in aMCL. Locked nucleic acid in situ hybridization showed increased staining of miR-15b in formalin-fixed paraffin-embedded sections of aMCL. These results correlated well with the microRNA microarray analysis. Although the molecular functions of miR-15b are largely unknown, it has been found to be associated with the cell cycle and apoptosis. However, the physiological significance of increased miR-15b in MCL is still unknown. Our present findings suggest that the upregulated expression of miR-15b is likely to play an important role in the transformation of cMCL to aMCL.
Collapse
Affiliation(s)
- Fumiko Arakawa
- Department of Pathology, School of Medicine, Kurume University, Kurume, Japan
| | - Yoshizo Kimura
- Department of Pathology, School of Medicine, Kurume University, Kurume, Japan
| | - Noriaki Yoshida
- Department of Pathology, School of Medicine, Kurume University, Kurume, Japan
| | - Hiroaki Miyoshi
- Department of Pathology, School of Medicine, Kurume University, Kurume, Japan
| | - Atushi Doi
- Cell Innovator Inc., Venture Business Laboratory of Kyushu University, Fukuoka, Japan
| | - Kaori Yasuda
- Cell Innovator Inc., Venture Business Laboratory of Kyushu University, Fukuoka, Japan
| | - Kazutaka Nakajima
- Department of Pathology, School of Medicine, Kurume University, Kurume, Japan
| | - Junichi Kiyasu
- Department of Pathology, School of Medicine, Kurume University, Kurume, Japan
| | - Daisuke Niino
- Department of Pathology, School of Medicine, Kurume University, Kurume, Japan
| | - Yasuo Sugita
- Department of Pathology, School of Medicine, Kurume University, Kurume, Japan
| | - Kosuke Tashiro
- Laboratory of Molecular Gene Technology and Molecular Biosciences, Department of Bioscience and Biotechnology, Faculty of Agriculture, Kyushu University, Fukuoka, Japan
| | - Satoru Kuhara
- Laboratory of Molecular Gene Technology and Molecular Biosciences, Department of Bioscience and Biotechnology, Faculty of Agriculture, Kyushu University, Fukuoka, Japan
| | - Masao Seto
- Department of Pathology, School of Medicine, Kurume University, Kurume, Japan
| | - Koichi Ohshima
- Department of Pathology, School of Medicine, Kurume University, Kurume, Japan
| |
Collapse
|
48
|
Tsukamoto Y, Fumoto S, Noguchi T, Yanagihara K, Hirashita Y, Nakada C, Hijiya N, Uchida T, Matsuura K, Hamanaka R, Murakami K, Seto M, Inomata M, Moriyama M. Expression of DDX27 contributes to colony-forming ability of gastric cancer cells and correlates with poor prognosis in gastric cancer. Am J Cancer Res 2015; 5:2998-3014. [PMID: 26693055 PMCID: PMC4656726] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/07/2015] [Accepted: 08/28/2015] [Indexed: 06/05/2023] Open
Abstract
Previously, we have reported that gain at chromosome 20q13 is the most common genomic copy number aberration in gastric cancer (GC) (29/30 cases), and that among the genes located in this region, we have identified DDX27, whose expression level shows the highest correlation with genomic copy number, as a candidate therapeutic target for GC. Here, we analyzed the clinicopathological significance of DDX27 using immunohistochemistry and studied its functions using knockdown assays. We found that DDX27 was frequently upregulated in GC tissues (98 of 140 cases, 70%), and significantly associated with venous invasion and liver metastasis. Furthermore, multivariate analysis of GC patients showed that high expression of DDX27 was independently associated with poorer prognosis. In functional assays, knockdown of DDX27 reduced the ability of GC cells to form colonies both on conventional plates and soft agar, but had little effect on their invasiveness. We also found that knockdown of DDX27 reduced the viability of GC cells through inhibition of cell cycle progression independently of apoptosis. Interestingly, DDX27 depletion induced accumulation of TP53 in a TP53 wild-type cell line, AGS, but not in a TP53-deleted cell line, 44As3, although DDX27 knockdown commonly reduced the viability of both, indicating the TP53-dependent and independent cell cycle control of DDX27. Thus, our results suggest that expression of DDX27 contributes to colony formation by GC cells through cell cycle control and may be a potential therapeutic target for GC patients with chromosome gain at 20q13.
Collapse
Affiliation(s)
- Yoshiyuki Tsukamoto
- Department of Molecular Pathology, Faculty of Medicine, Oita UniversityOita, Japan
| | - Shoichi Fumoto
- Department of Molecular Pathology, Faculty of Medicine, Oita UniversityOita, Japan
- Department of Gastroenterological and Pediatric Surgery, Faculty of Medicine, Oita UniversityOita, Japan
| | - Tsuyoshi Noguchi
- Center for Community Medicine, Division of Surgery, Faculty of Medicine, Oita UniversityOita, Japan
| | - Kazuyoshi Yanagihara
- Division of Pathology, Exploratory Oncology Research & Clinical Trial Center, National Cancer CenterChiba, Japan
| | - Yuka Hirashita
- Department of Molecular Pathology, Faculty of Medicine, Oita UniversityOita, Japan
- Department of Gastroenterology, Faculty of Medicine, Oita UniversityOita, Japan
| | - Chisato Nakada
- Department of Molecular Pathology, Faculty of Medicine, Oita UniversityOita, Japan
| | - Naoki Hijiya
- Department of Molecular Pathology, Faculty of Medicine, Oita UniversityOita, Japan
| | - Tomohisa Uchida
- Department of Molecular Pathology, Faculty of Medicine, Oita UniversityOita, Japan
| | - Keiko Matsuura
- Department of Molecular Pathology, Faculty of Medicine, Oita UniversityOita, Japan
| | - Ryoji Hamanaka
- Department of Cell Biology, Faculty of Medicine, Oita UniversityOita, Japan
| | - Kazunari Murakami
- Department of Gastroenterology, Faculty of Medicine, Oita UniversityOita, Japan
| | - Masao Seto
- Department of Pathology, Kurume University School of MedicineFukuoka, Japan
| | - Masafumi Inomata
- Department of Gastroenterological and Pediatric Surgery, Faculty of Medicine, Oita UniversityOita, Japan
| | - Masatsugu Moriyama
- Department of Molecular Pathology, Faculty of Medicine, Oita UniversityOita, Japan
| |
Collapse
|
49
|
Utsunomiya A, Tokunaga M, Nakano N, Kubota A, Takeuchi S, Takatsuka Y, Yoshida N, Seto M. Chronic type adult T-cell leukemia-lymphoma after autolougous stem cell transplantation for ALK-negative anaplastic large cell lymphoma. Retrovirology 2015. [PMCID: PMC4577864 DOI: 10.1186/1742-4690-12-s1-p25] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
|
50
|
Yoshida N, Tsuzuki S, Karube K, Takahara T, Suguro M, Miyoshi H, Nishikori M, Shimoyama M, Tsukasaki K, Ohshima K, Seto M. STX11 functions as a novel tumor suppressor gene in peripheral T-cell lymphomas. Cancer Sci 2015; 106:1455-62. [PMID: 26176172 PMCID: PMC4637999 DOI: 10.1111/cas.12742] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/10/2015] [Revised: 07/07/2015] [Accepted: 07/09/2015] [Indexed: 12/28/2022] Open
Abstract
Peripheral T-cell lymphomas (PTCL) are a heterogeneous group of non-Hodgkin lymphomas with poor prognosis. Their molecular pathogenesis has not been entirely elucidated. We previously showed that 6q24 is one of the most frequently deleted regions in primary thyroid T-cell lymphoma. In this study, we extended the analysis to other subtypes of PTCL and performed functional assays to identify the causative genes of PTCL that are located on 6q24. Genomic loss of 6q24 was observed in 14 of 232 (6%) PTCL cases. The genomic loss regions identified at 6q24 always involved only two known genes, STX11 and UTRN. The expression of STX11, but not UTRN, was substantially lower in PTCL than in normal T-cells. STX11 sequence analysis revealed mutations in two cases (one clinical sample and one T-cell line). We further analyzed the function of STX11 in 14 cell lines belonging to different lineages. STX11 expression only suppressed the proliferation of T-cell lines bearing genomic alterations at the STX11 locus. Interestingly, expression of a novel STX11 mutant (p.Arg78Cys) did not exert suppressive effects on the induced cell lines, suggesting that this mutant is a loss-of-function mutation. In addition, STX11-altered PTCL not otherwise specified cases were characterized by the presence of hemophagocytic syndrome (67% vs 8%, P = 0.04). They also tended to have a poor prognosis compared with those without STX11 alteration. These results suggest that STX11 plays an important role in the pathogenesis of PTCL and they may contribute to the future development of new drugs for the treatment of PTCL.
Collapse
Affiliation(s)
- Noriaki Yoshida
- Division of Molecular Medicine, Aichi Cancer Center Research Institute, Nagoya, Japan.,Department of Cancer Genetics, Nagoya University Graduate School of Medicine at Aichi Cancer Center Research Institute, Nagoya, Japan.,Department of Pathology, Kurume University School of Medicine, Kurume, Japan
| | - Shinobu Tsuzuki
- Division of Molecular Medicine, Aichi Cancer Center Research Institute, Nagoya, Japan
| | - Kennosuke Karube
- Division of Molecular Medicine, Aichi Cancer Center Research Institute, Nagoya, Japan
| | - Taishi Takahara
- Division of Molecular Medicine, Aichi Cancer Center Research Institute, Nagoya, Japan.,Department of Pathology and Laboratory Medicine, Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - Miyuki Suguro
- Division of Molecular Medicine, Aichi Cancer Center Research Institute, Nagoya, Japan
| | - Hiroaki Miyoshi
- Department of Pathology, Kurume University School of Medicine, Kurume, Japan
| | - Momoko Nishikori
- Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan
| | - Masanori Shimoyama
- Multi-institutional Clinical Trial Support Center, National Cancer Center, Tokyo, Japan
| | - Kunihiro Tsukasaki
- Department of Hematology, National Cancer Center Hospital East, Kashiwa, Japan
| | - Koichi Ohshima
- Department of Pathology, Kurume University School of Medicine, Kurume, Japan
| | - Masao Seto
- Division of Molecular Medicine, Aichi Cancer Center Research Institute, Nagoya, Japan.,Department of Cancer Genetics, Nagoya University Graduate School of Medicine at Aichi Cancer Center Research Institute, Nagoya, Japan.,Department of Pathology, Kurume University School of Medicine, Kurume, Japan
| |
Collapse
|